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Abstract: Signal transducer and activator of transcription 3 (STAT3) is a validated anticancer target
due to the relationship between its constitutive activation and malignant tumors. Through a virtual
screening approach on the STAT3-SH2 domain, 5,6-dimethyl-1H,3H-2,1,3-benzothiadiazole-2,2-
dioxide (1) was identified as a potential STAT3 inhibitor. Some benzothiadiazole derivatives were
synthesized by employing a versatile methodology, and they were tested by an AlphaScreen-based
assay. Among them, benzosulfamide 1 showed a significant activity with an IC50 = 15.8 ± 0.6 µM
as a direct STAT3 inhibitor. Notably, we discovered that compound 1 was also able to interact
with cysteine residues located around the SH2 domain. By applying mass spectrometry, liquid
chromatography, NMR, and UV spectroscopy, an in-depth investigation was carried out, shedding
light on its intriguing and unexpected mechanism of interaction.
Keywords: benzosulfamides; structure-based virtual screening; STAT3-SH2 domain; cysteine binder;
diversity-oriented synthesis
1. Introduction
Since the discovery of the relationship between the constitutive activation of signal transducer
and activator of transcription 3 (STAT3) and malignant tumors, the validation of STAT3 as a target
has been supported by a large number of studies. Various compounds with STAT3 inhibitory activity
have been reported in recent years, including potent inhibitors such as Stattic, S3I-201, and erasin [1–4].
Nevertheless, these molecules are mostly at the experimental stage, and only few are in clinical trials [5].
Hence, the challenge is the discovery of new selective candidates with high potency and in vivo activity.
Since a direct inhibitory approach should be preferred, we addressed our efforts to the disruption of
STAT3 homodimerization, an essential step in its activation, targeting the protein–protein interactions
(PPIs). The large surface area of STAT3 and the chemistry of these interactions [6], which are very
different from those of better-known targets such as enzymes and G-protein-coupled receptors, could
represent significant hurdles, although a number of successful examples have demonstrated that it is
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possible to overcome them and develop PPI modulators [7]. Since the binding of a ligand to a hot spot
should compete with the original protein partner of the PPI, thus resulting in disruption of its function,
the aim of our ongoing studies [8–13] is the identification of small molecules that are able to bind the Src
homology 2 (SH2) domain of STAT3, preventing STAT3 dimerization and thus its activation. With this
purpose, in the present work, some compound libraries were analyzed by means of a structure-based
virtual screening performed on the STAT3-SH2 domain (see the Molecular Modeling section). Among
the candidates that reached the best scores in the docking study, we decided to focus our attention on
the compounds that bear a sulfone moiety, which is a common feature in some STAT3-SH2 inhibitors
reported in the literature [1,2].
In order to support the docking results, the selected compounds were either purchased or
synthesized, and their ability to interact with the STAT3-SH2 domain was evaluated via an in vitro
binding test (AlphaScreen-based assay) at 30 µM; the most interesting results are reported in Table 1.
Hence, we identified the benzothiadiazole derivative 1 as a promising hit compound that carries a
chemically accessible moiety for further development.
Table 1. Inhibitory activities of compounds 1 and I–III.
Compound Structure % Inhibition
1
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The significant inhibitory activity exhibited by 5,6-dimethyl-1H,3H-2,1,3-benzothiadiazole-2,2-
dioxide (1) prompted us to fully characterize it by means of an X-ray analysis. Moreover, we designed 
and synthesized a small library of derivatives bearing different substituents on the aromatic and 
thiadiazole rings (1a–i, 2a,b, 3, 4). Furthermore, imidazol-2-one (5) and thiophene dioxide (6) moieties 
(replacing the thiadiazole ring (Figure 1)) were assessed to develop a preliminary structure-activity 
relationship (SAR) on this class of compounds. 
For the synthesis of 1a–i, we employed an adaptable methodology [14] that also considered a 
diversity-oriented approach using suitable monoprotected intermediates. For derivatives 2a,b, 3, and 4, 
our synthetic strategy was planned to allow for the introduction of different substituents on 
compound (1) by the direct alkylation of the sulfamide moiety. 
Herein, we describe the in silico-based rational design, synthesis, characterization, and interaction 
with the STAT3-SH2 domain of new inhibitors bearing the benzosulfamide scaffold. Furthermore, 
since several STAT3 inhibitors have been reported as irreversible cysteine binders (e.g., Stattic and 
S3I-201) [15–18], we decided to evaluate the activity of compound 1 versus the cysteine residues located 
around the STAT3-SH2 domain (Cys468, Cys542, Cys550, Cys687, and Cys712) and to shed light on 
its mechanism of interaction by MS, UV, LC, and NMR studies. 
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thiadiazole rings (1a–i, 2a,b, 3, 4). rt r r , i i az l-2- e (5) a thiophene dioxide (6) moieties
(replacing the thiadiazole ring (Figure 1)) were assessed to develop a preliminary structure-activity
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For the synthesis of 1a–i, we employed an adaptable methodol [14] that also considere a
diversit - i t si suita l ono rotect inter e i t . i ti , , , ,
our synthetic strategy was planned to all w for the introduction of different substituent on compound
(1) by the irect alkylation of the sulfamide moiety.
Herein, we describe the in silico-based rational design, synthesis, characterization, and interaction
with the STAT3-SH2 domain of new inhibitors bearing the benzosulfamide scaffold. F rt r r ,
since several STAT3 inhibitors have been reported as ir eversible cysteine binders (e.g., Stattic and
S3I-201) [15–18], e eci ed to eval ate the activity of co pound 1 versus the cysteine residues located
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2. Results and Discussion
2.1. Molecular Modeling—Design and Chemical Space Exploration
In order to identify new direct STAT3 inhibitors, molecular modeling studies were carried out.
In particula , a virtual screening approach was applied to comp und databases with the aim to
select a series of candidates endowed with the best binding scores. Ther fore, we perform d a
structure-b sed virtual scre ning, choosing STAT3 in complex with a DNA f agment (Protein Data
Bank (PDB) ID 1BG1) [19] as a model and mploying a set of databases of sm ll molecules, namely:
AKos (544391 molecul s), ChemPDB (4009), ChemBank (2344), Kyoto Encyclopedia of Genes and
Genomes–Compound (KEGG, 10005), National Cancer Institute Anti-HIV( NCI’ A ti-HIV, 42689),
and National Cancer Institute (NCI, 15237).
Each mol cule was ranked on the basis of the docking score (interaction energy of AutoDock
4) [20] of the best solution. In this way, a list of compounds was obtained i which the first and
the las mol cules were, respectively, the best and the orst interact g ones. This list mad the
next step of th analysis easier because only the first 500 ompounds for each database wer further
consider d. Hence, th best molecules were classified on the b sis of the most recurre t moi ties: (e.g.,
sulfonic acids, sulfonamide , sulfamates, pho pha es, and diketones; Tabl s S1–S5, Supplementary
Materials). This kind of clustering was performed by encoding the moieti s into SMARTS pattern
and performing queries on the atabases of the top-ranked p ses, as im leme ted in the VEGA
ZZ program. These results were very interesting because the funct onal groups included negativ ly
charged atoms, such as oxygens, which ca mimic the hosphat moiety of Tyr705 (pTyr-705), upon
interaction with positively charged amino acids. A further selection was p formed based on the
ommercial availability, synthetic a cessibility, and size of the molecules. In particul r, small molecules
were privileged because, in the fut re, they may be included in peptidic derivatives to improve their
selectivity. Therefore, drawing inspiration from compounds eported in th literature [1,2], we decided
to focus the cy lic sulfo amide moiety, ultima ly sel cting compoun s with a molecular weight
lower than 300 Da. The biological activity of several candidates belonging to t e NCI collection was
evaluated by an AlphaScreen-based ssay, nd am the most interesting h ts, compound 1 emerged
as a promising lead for further development (Table 1). T e analysis of its docking pose (see Figure S1)
revealed that com ound 1 may interact with the SH2 domain through th insertion of its sulfonamide
moiety i to the polar pocket lined by Arg-609 and Lys-591; mor over, it showed that the compound
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occupies most of the pocket volume normally filled by pTyr-705 in the dimerized STAT3. Starting from
this qualitative analysis of the binding mode, it seems reasonable to hypothesize that this molecule
could act as a reversible inhibitor of STAT3 dimerization.
2.2. Chemistry
Compounds 1 and 1a–d were synthesized from the corresponding commercially available
ortho-diamines through a direct cyclization in the presence of sulfamide and diglyme (Scheme 1) [21].
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Compound 1 showed acidic properties (pKa = 6.88 ± 0.03) [22] and was fully characterized by
X-ray diffraction. Its crystal structure is shown in Figure 2 as an ORTEP [23] drawing (Figure 2).
Molecules 2020, 25, x FOR PEER REVIEW 4 of 29 
 
qualitative analysis of the binding mode, it seems reasonable to hypothesize that this molecule could 
act as a r versible inhibitor of STAT3 dimerization. 
2.2. Chemistry 
Co pounds 1 and 1a–d were synthesized from the corresponding commercially available ortho-
diamines through  direct cyclizatio  in the presence of sulfamide and diglyme (Scheme 1) [21]. 
1   R,
 
R1
 = CH3
1a
 
R
 , R1
 = H
1b R
 = CH3
, R1
 = H
1c R = CF3
, R1
 = H
1d R = NO2
, R1
 = H
NH2
NH2
R1
R NH
SO2
H
NR1
R
 
Scheme 1. Reagents and conditions: NH2SO2NH2, diglyme, reflux, 40 min (10 min for compound 1). 
Compound 1 showed acidic properties (pKa = 6.88 ± 0.03) [22] and was fully characterized by X-
ray diffractio . Its crystal structure is shown in Figure 2 as an ORTEP [23] drawing (Figu e 2).
 
Figure 2. ORTEP [23] view of compound 1 and the relative arbitrary atom-numbering scheme 
(the mal ellipsoids at 50% probability). 
Products 1e and 2a were obtained starting from 2,4-dichloro-1-nitrobenzene and 1,5-dibromo-2-
methyl-4-nitrobenzene, r spectively. They we e reacted with 2,4-dim thoxybe zylamine (DMB-
NH2) or 4-methoxybenzylamine (PMB-NH2) to give in rmediates 7 and 8, resp ctively, which were 
converted to e corresponding amines 9 and 10 through eduction with zinc and ammonium lorid . 
By treatmen  with sulfamide, 9 and 10 underwent a cyclization reaction, thus affording ntermediat s 
11 and 12. These benzothiadiazole derivatives were deprotect d with trifluor acetic acid (TFA) to 
yield the final products 1e and 2a, respectively (Schem  2). 
Figure 2. ORTEP [23] view of c mp und 1 and the relative arb trary atom-numberi g sch me (thermal
ellipsoids at 50% probability).
Products 1e and 2a ere obtained starting from 2,4-dichloro-1-nitrobenzene and 1,5-dibromo-
2-methyl-4-nitrobenzene, respectively. They were reacted with 2,4-dimethoxybenzylamine (DMB-NH2)
or 4-methoxybenzylamine (PMB-NH2) to give intermediates 7 and 8, respectively, which ere
converted to the corresponding a ines 9 and 10 through reduction ith zinc and a oniu chloride.
By treat ent ith sulfa ide, 9 and 10 under ent a cyclization reaction, thus affording inter ediates
11 and 12. These benzothiadiazole derivatives were deprotected with trifluoroacetic acid (TFA) to yield
the final products 1e and 2a, respectively (Scheme 2).
Product 1f was obtained starting from compound 1d, which was protected by treatment with
PMB-Br and potassium carbonate to afford intermediate 13; its reduction with zinc and ammonium
chloride gave the amine 14. The latter, through a reaction with acetic anhydride, afforded intermediate
15, which was deprotected with TFA to give product 1f (Scheme 3).
Intermediate 19, the starting reagent for the synthesis of products 1g–i, was obtained as reported
in Scheme 4: the reaction of 2,5-dibromo-nitrobenzene with PMB-NH2 led to intermediate 16, which
was reduced to give the amine 17 in the presence of zinc and ammonium chloride. By treatment with
sulfamide, 17 was cyclized, thus affording the benzothiadiazole derivative 18, which was subsequently
protected with PMB-Br to yield compound 19 (Scheme 4).
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Intermediate 19, the starting reagent for the synthesis of products 1g–i, was obtained as reported 
in Scheme 4: the reaction of 2,5-dibromo-nitrobenzene with PMB-NH2 led to intermediate 16, which 
was reduced to give the amine 17 in the presence of zinc and ammonium chloride. By treatment with 
sulfamide, 17 was cyclized, thus affording the benzothiadiazole derivative 18, which was 
subsequently protected with PMB-Br to yield compound 19 (Scheme 4). 
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Scheme 4. Reagents and conditions: (a) PMB-NH2, reflux, 8 h; (b) Zn, NH4Cl, MeOH/H2O (9:1), reflux, 
4 h; (c) NH2SO2NH2, dry diglyme, 160 °C, 3 h; and (d) PMB-Br, dry K2CO3, dry DMF, 80 °C, 2 h. 
c . Reagents and conditions: (a) 2,4-dimethoxybenzylamine (DMB-NH2) (for 7) or
4-methoxybenzylamine (PMB-NH2) (for 8), isopropanol, reflux, 12 h; (b) , l, e / (9:1),
refl x, 3 h; (c) S , dry digly e, 160 ◦C, 1.5 h; and (d) trifluoroacetic aci ( F ), , 50 ◦ ,
1.5 h.
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Intermediate 19, the starting reagent for the synthesis of products 1g–i, was obtained as reported 
in Scheme 4: the reaction of 2,5-dibromo-nitrobenzene with PMB-NH2 led to intermediate 16, which 
was reduced to give the amine 17 in the presence of zinc and ammonium chloride. By treatment with 
sulfamide, 17 was cyclized, thus affording the benzothiadiazole derivative 18, which was 
subsequ ntly protected with PMB-Br to yield compound 19 (Sc eme 4). 
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Scheme 4. Reagents and conditions: (a) PMB-NH2, reflux, 8 h; (b) Zn, NH4Cl, MeOH/H2O (9:1), reflux, 
4 h; (c) NH2SO2NH2, dry diglyme, 160 °C, 3 h; and (d) PMB-Br, dry K2CO3, dry DMF, 80 °C, 2 h. 
Sche e 4. Reagents and conditions: (a) P B- , reflux, 8 h; (b) Zn, Cl, e / O (9:1), reflux,
4 h; (c) S 2NH2, dry diglyme, 160 ◦C, 3 h; and (d) PMB-Br, dry K2CO3, dry DMF, 80 ◦C, 2 h.
Afterwards, intermediate 19 was reacted with ethyl acrylate in the presence of tri-o-tolylphosphine
and tris(dibenzylideneacetone)dipalladium(0) to afford the ester 20. The latter was hydrolyzed under
basic conditions to the corresponding acid 21, which was converted to the amides 22 and 23 using
isopentylamine, HATU, and N,N-diisopropylethylamine or aniline, TBTU, and N-methylmorpholine,
respectively. By catalytic hydrogenation with 10% Pd/C, they were reduced and deprotected to give
products 1g and 1h (Scheme 5).
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Products 2b and 3 were obtained from compounds 1b and 1a, respectively, through alkylation 
with iodomethane or benzyl bromide in the presence of potassium carbonate (Scheme 7). 
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Product 4 was prepared through a reaction of 1-chloro-2-nitrobenzene with DMB-NH2 to obtain 
intermediate 25, which was reduced using zinc and ammonium chloride to give the amine 26. Its 
cyclization with sulfamide led to intermediate 27, which was firstly esterified with ethyl bromoacetate 
to give intermediate 28 and then hydrolyzed under basic conditions to the corresponding acid 29. 
This intermediate was condensed with 2-phenylethylamine to afford the amide 30, which was 
deprotected with TFA, thus leading to the product 4 (Scheme 8). 
Scheme 5. Reagents and conditions: (a) ethyl acrylate, P(o-tol)3, Pd2(dba)3, TEA, dry DMF, 80 ◦C, 20 h;
(b) 3 M NaOH, MeOH, 80 ◦C, 3 h; (c) isopentylamine, HATU, DIPEA, DCM, r.t., 20 h (for 22) or aniline,
TBTU, N-methylmorpholine, DCM, r.t., 24 h (for 23); and (d) H2 (3 atm), 10% Pd/C, EtOH, r.t., 48 h.
Moreover, compound 19 was arylated through a Suzuki reaction with phenylboronic acid in
the presence of tetrakis(triphenylphosphine)palladium(0) to give intermediate 24, which was then
deprotected by treatment with TFA, thus affording product 1i (Scheme 6).
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Product 4 was prepared through a reaction of 1-chloro-2-nitrobenzene with DMB-NH2 to obtain 
intermediate 25, which was reduced using zinc and ammonium chloride to give the amine 26. Its 
cyclization with sulfamide led to intermediate 27, which was firstly esterified with ethyl bromoacetate 
to give intermediate 28 and then hydrolyzed under basic conditions to the corresponding acid 29. 
This intermediate was condensed with 2-phenylethylamine to afford the amide 30, which was 
deprotected with TFA, thus leading to the product 4 (Scheme 8). 
Scheme 6. Reagents and conditions: (a) PhB(OH) , Pd(PPh ) , Na2CO3, 1,4-dioxane, reflux, 20 h; and
(b) TFA, DCM, r.t., 3 h.
Products 2b and 3 were obtained from compounds 1b and 1a, respectively, through alkylation
with iodomethane or benzyl brom d in the presence of potassium carbona e (Scheme 7).
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Product 4 as prepared through a reaction of 1-chloro-2-nitrobenzene ith B- 2 to obtain 
inter ediate 25, hich as reduced using zinc and a oniu  chloride to give the a ine 26. Its 
cyclization ith sulfa ide led to inter ediate 27, hich as firstly esterified ith ethyl bro oacetate 
to give inter ediate 28 and then hydrolyzed under basic conditions to the corresponding acid 29. 
This inter ediate as condensed ith 2-phenylethyla ine to afford t e a ide 30, hich as 
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c eme 7. ea e ts a c iti s: CH I (f r 2 ) r r (f r 3), r K CO3, and dry DMF, 80 ◦C, 2 h.
Product 4 was prepared through a reaction of 1-chloro-2-nitrobenzene with DMB-NH2 to obtain
intermediate 25, which was reduced using zinc and ammonium chlorid to give the amine 26. Its
cyclization with sulfamide led to intermediate 27, which was firstly esterifi d with thyl bromoacetate
to give intermediate 28 an the hydrolyzed under basic conditions to the corresponding acid
29. This intermediate w s condense with 2-phenylethylamine t afford the amide 30, which was
deprotected with TFA, thus leading to t e product 4 (Sche e 8).
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Product 5 was achieved through the cyclization of benzene-1,2-diamine in the presence of 
carbonyldiimidazole (CDI) (Scheme 9). 
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Scheme 9. Reagents and conditions: CDI, dry THF, reflux, 12 h. 
Finally, compound 6 was purchased from commercial sources. 
2.3. Biological Evaluation 
AlphaScreen is an in vitro competitive binding test used to identify compounds that are able to 
inhibit the binding of proteins containing an SH2 domain to their corresponding phosphopeptides 
(5-carboxyfluorescein (FITC)-GpYLPQTV for STAT3 and FITC-GpYDKPHVL for STAT1) (Table 2). 
Compounds characterized by an interesting STAT3 affinity were further investigated for their 
selectivity versus STAT1, which shows a high degree of sequence similarity to STAT3 but an opposite 
physiological role [24,25], and Grb2, as a model for other SH2 domain-containing proteins. 
The significant activity of compound 1, revealed at 30 µM (Table 2), prompted us to test this 
compound at different concentrations. Therefore, we calculated its IC50 values against STAT3 and 
STAT1 to be 15.8 ± 0.6 and ˃50 µM, respectively, while the inhibition versus Grb2 was 23% (at a 30 µM 
concentration). 
To identify a trend in terms of structure–activity relationship, we firstly explored the role of the 
substituents on the benzene ring (1a–i). In this respect, we found that lipophilicity does not play an 
important role in modulating STAT3 inhibitory activity. Bulky lipophilic substituents at position 5 
(derivatives 1g and 1h) induced a significant drop in the inhibition properties (Table 2). Among these 
derivatives, only 1d, bearing a NO2 group at position 5, exhibited a noticeable activity against STAT3. 
For this compound, we calculated the IC50 values against STAT3 and STAT1, which were 25.1 ± 2.6 µM 
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Scheme 8. Reagents and conditions: (a) DMB-NH2, EtOH, reflux, 12 h; (b) Zn, NH4Cl, MeOH/H2O
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Product 5 was achieved through the cyclization of benzene-1,2-diamine in the presence of
carbonyldiimidazole (CDI) (Scheme 9).
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Finally, compound 6 was purchased from commercial sources.
2.3. Biological Evaluation
AlphaScreen is an in vitro competitive binding test used to identify compounds that are able to
inhibit the bindi g of proteins c ntaining an SH2 domain to their corresponding phosphopeptides
(5-carboxyfluorescein (FITC)-GpYLPQTV for STAT3 and FITC-GpYDKPHVL for STAT1) (Table 2).
Compounds characterized by an interesting STAT3 affinity were further investigated for their selectivity
versus STAT1, which shows a high degree of sequence similarity to STAT3 but an opposite physi logical
role [24,25], and Grb2, as a model f r other SH2 domain-containing proteins.
The significant activity of compound 1, revealed at 30 µM (Table 2), prompted us to test this
compound at different concentrations. Therefore, we calculated its IC50 values against STAT3 and
STAT1 to be 15.8 ± 0.6 and >50 µM, respectively, while the inhibition versus Grb2 was 23% (at a 30 µM
concentration).
To identify a trend in terms of structure–activity relationship, we firstly explored the role of the
substituents on the benzene ring (1a–i). In this respect, we found that lipophilicity does not play
an important role in modulati g STAT3 i hibitory activity. B lky lipophilic substituents at positio
5 (derivatives 1g and 1h) induced a significant drop in the inhibition properties (Table 2). Among
these derivatives, only 1d, bearing a NO2 group at position 5, exhibited a noticeable activity against
STAT3. For this compou d, we calculated the IC50 values against STAT3 and STAT1, which were
25.1 ± 2.6 µM and 15.9 ± 2.0 µM, respectively, reveali g no selectivity for STAT3 inhibition. Then, we
i troduced different groups on the nitro e atoms of the thiadiazole ring (2a,b, 3, and 4), in order
to explore asymmetrical substitutions: The presence of the N-substituent id not improve activity.
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The enhanced bulkiness and hydrophobicity of these substituents compared to compound 1 did not
lead to a better interaction.
Table 2. Inhibitory activities of compounds 1, 1a–i, 2a–b, and 3–6. STAT3: signal transducer and
activator of transcription 3.
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Compound Substituents STAT3 % Inhibition (30 µM)
1 R, R1 = CH3; R2, R3 = H 96.5 ± 1.1 [a]
R, 1, 2, R3 = H 16.4 ± 0.8 [b]
R = H; R1 = CH3; 2, R3 = H 14.5 ± 0.6 [b]
1c R = H; R1 = CF3; R2, R3 = H 8.2 ± 1.6 [b]
1d R = H; R1 = NO2; R2, R3 = H 56.9 ± 3.6 [c]
1e R = H; R1 = Cl; R2, R3 = H 28.2 ± 1.4 [b]
1f R = H; R1 = NHCOCH3; R2, R3 = H 18.9 ± 2.3 [b]
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2a R = CH3; R1 = Br; R2, R3 = H 25.6 ± 1.2 [b]
2b R = H; R1, R2, R3 = CH3 8.9 ± 1.1 [b]
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Finally, we investigated the importance of the thiadiazole ring (5 and 6) through the exploration
of the function of the SO2 group and of the nitrogen atoms: The results of the AlphaScreen-based assay
indicated that these moieties play a key role in the interaction with the STAT3-SH2 domain.
Overall, our data seem to indicate that is class f benzothiadiazole derivatives s cha act rized
by an extremely “tight” SAR: M st of the modifications applied to the scaffold of compound 1 resulted
in a considerable loss of activity, with the sole exception of 1d, which retained a partial inhibitory effect.
Since from the literature it is known that some benzothiadiazoles could covalently bind to
proteins [26], an in silico prediction to evaluate whether the proposed derivatives were pan-assay
interference compounds (PAINS) was performed by submitting their structures to five on-line services
(FAF-Drugs4 [27], PAINS remove [28], SmartsFilter, (http://pasilla.health.unm.edu/tomcat/biocomp/
smartsfilter), SwissADME [29], and Zinc Patterns (http://zinc15.docking.org/patterns/home/)). Three of
them (SmartsFilter, wissADME, and Zinc Patterns) identified compounds 1, 1a–i, and 2 as potential
PAINS (see Table S6).
This result was experime tally confut d, at least for compound 1, bec use it as found to act as a
selective STAT3 inhibitor with an IC50 of 15.8 ± 0.6 µM, which was significantly lower than the IC50
shown versus STAT1 ( >50 µM). This selectivity was remarkable considering the high similarity and
identity of both STAT1 and STAT3, for the SH2 domain in particular (73.5% sequence similarity and
56.1% sequence identity, calculated by EMBOSS Needle [30]).
Furthermore, to gain insight into the activity of compound 1, its interaction with the cysteine
residues located in the vicinities of the SH2 domain (Figure 3) was investigated and evaluated by an
AlphaScreen-based assay using different mutants (Table 3).
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Table 3. Sensitivity of single-mutated STAT3 proteins (Cys468, Cys542, Cys550, Cys687, and Cys712) to
compound 1. SH2 binding to the phosphotyrosine peptide was assessed by the AlphaScreen assay.
The means ± SD were calculated from triplicate experiments.
Compound 1 vs. STAT3
Mutated Cys IC50 (µM) Mutated Cys IC50 (µM)
WT 15.8 ± 0.6 Cys550A >30
Cys468A >30 Cys687A >30
Cys542A >30 Cys712A >30
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partially contributes to the inhibition ediated by the olecule.
Though ST T3 contains t elve cysteine residues, the assays ere perfor ed only on clones
bearing utations on the five cysteines located near the ST T3-S 2 do ain. Therefore, e cannot
exclude the possibility that other cysteines ay be involved in the interaction ith co pound 1.
Considering the affinity of co pound 1 for ST T3 ild-type, e decided to explore its echanis
of interaction ith cysteines by eans of analytical studies.
In order to analyze the binding mode of compound 1 to the pockets containing the mutated
cysteine residues, a molecular docking study was carried out. In particular, we applied the same
protocol used for the virtual screening, but, in this case, the grid maps were calculated by selecting the
atoms included in a sphere of 12 Å radius that were centered on each cysteine residue. The so-obtained
complexes ere optimized with the same minimization protocol employed for the preparation of the
STAT3 crystal structure (30,000 steps of conjugate gradients minimization). For a better analysis of
the poses, the distances between the cysteine sulfur and the two hypothetical reactive centers (the
methyl in 5 and the aromatic carbon in 4) of compound 1 were evaluated. The results in Table S9 show
that only the complex with Cys712 seems to have the suitable prerequisites in terms of distances to
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the reactive centers (4.70 and 4.95 Å for CH3–S and CH–S, respectively; see Figure S72) and docking
energy (−5.93 Kcal/mol), even if the latter parameter must be taken into account with caution because
it was calculated by molecular mechanics. The complex with Cys550 also seemed to have the right
distances to react with compound 1 (3.64 and 5.13 Å for CH3–S and CH–S, respectively); however,
the interaction energy was found to be significantly worse than that of the complex with Cys712
(−3.52 versus −5.93 Kcal/mol). Unfortunately, this kind of behavior could not be confirmed by the
experimental data; this was probably due to the intrinsic problem afflicting all docking calculations
that could only evaluate the physicochemical and steric complementarity of two interacting partners
and not the reactivity of the atoms.
2.4. Analytical Studies
2.4.1. MS, UV, and LC Studies
MS studies revealed that compound 1 reacts with glutathione (GSH, used as a model for
cysteine-containing peptides) to generate stable covalent adducts. Since no adducts were detectable
at the incubation starting point, such reactions did not take place during sample transfer into the
MS analyzer. Similar approaches have already been used to identify reactive intermediates by MS
studies [31]. The reaction was pH-dependent and required a neutral or basic pH to take place, whereas
no reactivity was observed at an acidic pH (Figure 4).
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Figure 4. MS spectra of glutathione (GSH) incubated with compound 1 as recorded at incubation
starting point (A), at incubation endpoint in a pH 2 buffer (B), at incubation endpoint in a pH 7.4
buffer (C), and at incubation endpoint in a pH 10 buffer (D).
The absence of reactivity at the acidic pH can be explained on one hand by the pH-dependent
nucleophilicity of GSH [32] and on the other hand by the deprotonation of compound 1 occurring at a
neutral/basic pH (pKa = 6.88 ± 0.03) [22], which can lead to structure rearrangements that possibly
contribute to an increased reactivity towards GSH. However, the methyl groups seem fundamental for
the covalent reaction, since no adducts were detectable upon incubation of GSH with compound 1d,
which was the second most active compound according to the results reported in Table 2.
At a neutral pH (Figure 4C), a single adduct was detectable at the reaction endpoint (504.12121 m/z),
whereas at a basic pH (Figure 4D), three signals at 502.10569, 504.12120, and 520.11607 m/z were
detected along with the complete oxidation of GSH to its dimer GSSG (i.e., the conversion of the singly
charged GSH ion at 308.09106 m/z to the doubly charged GSSG ion at 307.08332 m/z).
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The signals at 502.10569, 504.12120, and 520.11607 m/z were all within 1 ppm from the theoretical
m/z values expected for singly charged ions of molecules C18H25N5O8S2, C18H23N5O8S2, and
C18H25N5O9S2, respectively.
Interestingly, at pH 10, the adducts were also detected at the incubation starting point if compound
1 was added before GSH into the buffer (Figure 5A), but not if GSH (Figure 5B) or Na2S2O5 (Figure 5C)
were added into the buffer before compound 1.
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10 (spectra A and B). Samples were prepared by adding compound 1 (spectrum A) or GSH (spectrum
B) as the first reagent. MS spectra at the incubation starting point (spectrum C) and endpoint (spectrum
D) for a 1:1 GSH:compound 1 mixture incubated at pH 10 with Na2S2O5 in the buffer.
Since GSH is an antioxidant, we speculated on the involvement of oxidation steps for the formation
of adducts. To address such a hypothesis, the experiments were repeated in a buffer containing Na2S2O5,
which had similar effect of GSH at the incubation starting point (Figure 5C) and prevented the formation
of adducts at 502.10569 and 520.11607 m/z at the incubation endpoint (Figure 5D), suggesting that such
adducts are generated only in oxidizing conditions.
On the contrary, the adduct at 504.12130 m/z was detectable at the incubation endpoint, despite
Na2S2O5 addition (Figure 5D).
Consistently with MS data, LC-UV experiments detected a single adduct when compound 1 was
incubated with GSH and Na2S2O5 (i.e., chromatographic peak at RT = 8.7 min, Figure 6B), whereas
multiple peaks were generated if no antioxidants were added into the buffer (Figure 6C).
Na2S2O5 also prevented the complete consumption of compound 1 (Figure 5B), thus confirming
that oxidizing conditions trigger a faster reaction rate.
Moreover, despite MS experiments detecting an adduct at 504.12125 ± 0.00006 m/z, both with
and without Na2S2O5, the corresponding chromatograms had no common peaks. This means that
oxidizing and non-oxidizing conditions lead to the formation of adducts with different structures but
the same elemental composition.
This hypothesis was also supported by the UV spectra collected for the corresponding reaction
batches. As reported in Figure 6, the UV spectra at the reaction endpoint look alike for reactions
buffered at pH 7.4 or pH 10 with Na2S2O5, with no shifts compared to the starting point (data not
shown). On the contrary, the incubation at pH 10 without Na2S2O5 was only found to have a similar
shape at the starting point, while a significant shift was observed at the reaction endpoint (Figure 7).
Molecules 2020, 25, 3509 12 of 29
Molecules 2020, 25, x FOR PEER REVIEW 12 of 29 
 
 
Figure 6. Chromatograms of GSH incubated with compound 1 as recorded at incubation starting 
point (A), at incubation endpoint in a pH 10 buffer containing Na2S2O5 (B), and at incubation endpoint 
in a Na2S2O5-free pH 10 buffer (C). 
Na2S2O5 also prevented the complete consumption of compound 1 (Figure 5B), thus confirming 
that oxidizing conditions trigger a faster reaction rate. 
Moreover, despite MS experiments detecting an adduct at 504.12125 ± 0.00006 m/z, both with 
and without Na2S2O5, the corresponding chromatograms had no common peaks. This means that 
oxidizing and non-oxidizing conditions lead to the formation of adducts with different structures but 
the same elemental composition. 
This hypothesis was also supported by the UV spectra collected for the corresponding reaction 
batches. As reported in Figure 6, the UV spectra at the reaction endpoint look alike for reactions buffered 
at pH 7.4 or pH 10 with Na2S2O5, with no shifts compared to the starting point (data not shown). On the 
contrary, the incubation at pH 10 without Na2S2O5 was only found to have a similar shape at the 
starting point, while a significant shift was observed at the reaction endpoint (Figure 7). 
 
Figure 7. UV spectra at the endpoint of the reaction between GSH and compound 1. Reaction was 
buffered at pH 7.4 (blue line), pH 10 (green line), or pH 10 with Na2S2O5 (orange line). 
The reaction mechanism in Figure 8 accounts for all the observations described above. 
Specifically, the overall mechanism requires a neutral-to-basic pH for compound 1 deprotonation 
to generate adducts. All included oxidation steps are dependent on the basic pH activation of compound 
Figure 6. Chromatograms of GSH incubated with compound 1 as recorded at incubation starting point
(A), at incubation endpoint in a pH 10 buffer containing Na2S2O5 (B), and at incubation endpoint in a
Na2S2O5-free pH 10 buffer (C).
Molecules 2020, 25, x FOR PEER REVIEW 12 of 29 
 
 
Figure 6. Chromatograms of GSH incubated with compound 1 as recorded at incubation starting 
point (A), at incubation endpoint in a pH 10 buffer containing Na2S2O5 (B), and at incubation endpoint 
in a Na2S2O5-free pH 10 buffer (C). 
Na2S2O5 also prevented the complete consumption of compound 1 (Figure 5B), thus confirming 
that oxidizing conditions trigger a faster reaction rate. 
Moreover, despite MS experiments detecting an adduct at 504.12125 ± 0.00006 m/z, both with 
and without Na2S2O5, the corresponding chromatograms had no common peaks. This means that 
oxidizing and non-oxidizing conditions lead to the formation of adducts with different structures but 
the same elemental composition. 
This hypothesis was also supported by the UV spectra collected for the corresponding reaction 
batches. As reported in Figure 6, the UV spectra at the reaction endpoint look alike for reactions buffered 
at pH 7.4 or pH 10 with Na2S2O5, with no shifts compared to the starting point (data not shown). On the 
contrary, the incubation at pH 10 without Na2S2O5 was only found to have a similar shape at the 
starting point, while a significant shift was observed at the reaction endpoint (Figure 7). 
 
Figure 7. UV spectra at the endpoint of the reaction between GSH and compound 1. Reaction was 
buffered at pH 7.4 (blue line), pH 10 (green line), or pH 10 with Na2S2O5 (orange line). 
The reaction mechanism in Figure 8 accounts for all the observations described above. 
Specifically, the overall mechanism requires a neutral-to-basic pH for compound 1 deprotonation 
to generate adducts. All included oxidation steps are dependent on the basic pH activation of compound 
Figure 7. UV spectra at the endpoint of the reaction between GSH and compound 1. Reaction was
buffered at pH 7.4 (blue line), pH 10 (green line), or pH 10 with Na2S2O5 (orange line).
The reaction mechanism in Figure 8 accounts for all the observations described above.
Specifically, the overall mechanism requires a neutral-to-basic pH for compound 1 deprotonation to
generate adducts. All included oxidation steps are dependent on the basic pH activation of compound
1, like with catechol [33], and provide the generation of reactive intermediates similar to quinones and
quinone-methides that are able to covalently react with GSH [34–36]. The final products VIb and VIIa
are generated only after the oxidative rearrangement of compound 1 and have molecular formulas in
agreement with the MS signals at 502 and 520 m/z, found only in reaction batches without antioxidants.
The products IVa and IIb were found to have the same molecular formula, which was in agreement
with the signal at 504 m/z that was found in reaction batches with or without antioxidants. However,
consistently with LC experiments, the products IVa and IIb were found to have different structures
and formation mechanisms: IVa was found to be generat d after comp und 1 oxidation, while the
formation of IIb was not fou d to require the oxidation of compound 1. Interest gly, such mechanism
is not specific for the class of compounds since it was only observed for compound 1. The removal of
Molecules 2020, 25, 3509 13 of 29
the methyl groups led to compounds that were unable to covalently react with glutathione, despite
some of them still being capable of inhibiting STAT3 activity (e.g., compound 1d; see Table 2).
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2.4.2. 1H-NMR Analysis
With the aim of confirming the stated hypotheses, NMR studies were performed in the experimental
conditions previously considered for the MS analysis in the absence or in the presence of GSH. Actually,
few NMR studies concerning covalent interactions between GSH/STAT proteins and small molecules
have been reported. In one case [37], the authors exploited the presence of fluorine atoms on the
studied compounds and used 19F-NMR spectroscopy, which has the advantage of simple spectra with
a wide spread of resonances.
In our case, we used 1H-NMR spectroscopy even though it is known that GSH, like other small
peptides, presents a great conformational variability, also depending on the pH, that influences its
ionization state [38]; consequently, its 1H-NMR spectra could appear quite complex.
Therefore, to study the interaction of compound 1 with the model peptide GSH, we decided to
perform a comparison, at different times, of the spectra of compound 1 and of GSH alone with the
spectrum of a mixture of them at pH 10 and 37 ◦C. These conditions were chosen because they proved
to be optimal for the interaction between the two compounds in the MS investigations. Moreover,
in order to make the NMR study easier, we decided to add Na2S2O5 to the mixture to reduce the
number of adducts that could potentially derive from the reactions between compound 1 and GSH.
The use of this reducing agent made the MS spectra less complex, mainly showing a 504 [M + H]+
ion (Figure 5D) corresponding to few hypothetical structures (IIb and IVa; Figure 8); in the same
conditions, the LC chromatogram revealed essentially one peak at 8.7 min, even if this analysis showed
only a reduced transformation of the starting compound 1 at the incubation endpoint (Figure 6B).
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Moreover, the addition of Na2S2O5 should have prevented the presence of interfering NMR resonances
due to the formation of oxidized GSSG.
Though this study did not demonstrate the formation of the expected compounds (see discussion
in Supplementary Materials and Figures S72–S74), we believe that the NMR outcomes cannot disprove
the results obtained by MS spectroscopy.
3. Experimental Section
3.1. Computational Methods
The structural coordinates of STAT3, co-crystallized with a DNA fragment, were downloaded
from the Protein Data Bank (PDB ID 1BG1) [19]. The protein was dimerized by applying the
transformation matrix, as shown in the PDB file, and the model was completed by the addition
of the hydrogens in two steps: (1) to STAT3, applying the algorithm for proteins, and (2) to DNA,
applying the algorithm for nucleic acids. In both cases, we used the features included in the VEGA
ZZ package [39]. Atom charges (Gasteiger–Marsili method) [40] and potentials (CHARMM 22 for
proteins and nucleic acids) [41,42] were assigned to the obtained structure. Finally, the model was
optimized by a conjugate gradient minimization (30,000 steps) to reduce the high-energy steric
interactions. In order to preserve the experimental data, atom constraints were applied to protein and
DNA backbones. This step was carried out by NAMD 2.13 [43], which was integrated in the VEGA
ZZ graphic environment. To perform virtual screening calculations, the following databases were
chosen: AKos (AKos Consulting & Solutions GmbH, Steinen, Germany; 544,391 molecules), ChemPDB
(4009), ChemBank (Broad Institute, Cambridge, MA, USA; 2344), KEGG (Kyoto Encyclopedia of
Genes and Genomes, Kanehisa Laboratories, Kyoto, Japan; 10005), NCI’s Anti-HIV (National Cancer
Institute, National Institute of Health, USA; 42689), and NCI (National Cancer Institute, National
Institute of Health, USA; 15237). These databases are available for free at the mirror site of Ligand.info
(http://biophysics.med.jhmi.edu/~{}yliu120/dockingdatabase.html; the original database site is no
longer available) [44], which includes collections of compounds for virtual screening. These structures
are already converted to 3D and fully optimized by molecular mechanics. Nevertheless, all molecules
were pre-processed setting their ionization state at a physiological pH, and the resulting structures were
optimized and refined by PM7 semi-empirical method, as implemented in MOPAC 2016. To perform
this calculation, the WarpEngine technology implemented in VEGA ZZ [45] was used, reducing the
computational time to few tens of minutes for the whole dataset through the distribution of the MOPAC
calculation on a network of PCs. In more detail: Three blade servers equipped with two CPUs, each of
Intel Xeon E5 class, were used for a total of 52 physical cores and 104 threads. The virtual screening
was carried out by the GriDock software, which was especially designed to run on high performance
computing systems (HPC) and distributed computer resources (GRID) as front-end to the well-known
AutoDock 4 package [20]. Specifically, GriDock is able to extract each molecule from a database
and perform a docking calculation through AutoDock 4. Though it is currently possible to perform
screenings with faster and more efficient programs, we preferred to spend more time on the calculation
because we had already obtained good results with AutoDock in previous studies on STAT3. Before
running GriDock, a single STAT3 monomer was considered, and the grid maps, required to evaluate
docking scores, were calculated by selecting the atoms included in a sphere of 12 Å radius centered on
the phosphorylated Tyr-705 (PTR-705 in the PDB file). This pocket represented a possible hot spot of
interaction with STAT3 for ligands, since it is known to play a pivotal role in STAT3 dimerization and
activation. This process was carried out by AutoGrid 4 interfaced to VEGA ZZ. The compounds of
the considered databases were docked by GriDock/AutoDock using the genetic-algorithm search and
generating ten possible solutions.
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3.2. Chemistry
3.2.1. Materials and Methods
All starting materials, chemicals, and solvents were purchased from commercial suppliers
(Sigma-Aldrich-Merck, St. Louis, MI, USA; FluoroChem, Hadfield, UK) and used as received.
Anhydrous solvents were utilized without further drying. Aluminum-backed silica gel 60 plates
(0.2 mm; Merck, Darmstadt, Germany) were used for analytical thin-layer chromatography (TLC)
to follow the course of the reactions. Silica gel 60 (40–63 µm; Merck) was used for the purification
of intermediates and final compounds through flash column chromatography. Melting points were
determined in open capillary tubes with a Stuart SMP30 Melting Point Apparatus (Cole-Parmer Stuart,
Stone, UK) and are uncorrected. 1H and 13C-NMR spectra were acquired at ambient temperature with
a Varian Oxford 300 MHz instrument (Varian, Palo Alto, CA, USA),operating at 300 MHz for 1H and
75 MHz for 13C. Chemical shifts are expressed in ppm (δ) from tetramethylsilane (TMS) resonance
in the indicated solvent (TMS: δ = 0.0 ppm), while J-couplings are given in hertz. All the spectra
are reported in the Supplementary Materials. The purity of the tested compounds was assessed by
means of elemental analysis using a EuroVector EA 3000 CHNS-O analyzer (EuroVector, Pavia, Italy).
All experimental values are within ±0.40% of the theoretical predictions, indicating a ≥95% purity.
3.2.2. Synthetic Procedures
5,6-Dimethyl-1H,3H-2,1,3-benzothiadiazole-2,2-dioxide, 1
Procedure A: To a solution of 4,5-dimethyl-1,2-phenylenediamine (100 mg, 0.73 mmol) in dry
diglyme (0.75 mL) under reflux, sulfamide (86 mg, 0.89 mmol) dissolved in dry diglyme (0.73 mL) was
slowly added. The mixture was stirred for 10 min at 160 ◦C. After cooling, the dark brown mixture
was diluted with ice-H2O and extracted with EtOAc (3 × 5 mL). The organic phase was washed
repeatedly with cold H2O to remove the diglyme. Then, it was treated with Na2SO4, filtered, and
evaporated under reduced pressure. The crude product was purified by flash column chromatography
(cyclohexane/EtOAc 8:2) to obtain 1 as a brownish solid. Yield: 50%. TLC (cyclohexane/EtOAc 8:2): Rf:
0.36. Mp: 148 ◦C. 1H-NMR (300 MHz, acetone-d6): δ 9.25 (s, 2H, NH), 6.72 (s, 2H, ArH), 2.18 (s, 6H,
CH3) ppm. 13C-NMR (75 MHz, D2O): δ 134.6, 127.0, 111.1, 18.4 ppm. Anal. calcd (%) for C8H10N2O2S:
C, 48.47; H, 5.08; N, 14.13; S, 16.17; found: C, 48.21; H, 5.03; N, 14.67; S, 16.34.
1H,3H-2,1,3-Benzothiadiazole-2,2-dioxide, 1a
Benzene-1,2-diamine was reacted for 1.5 h using Procedure A; the purification was performed by
flash column chromatography (cyclohexane/EtOAc 6:4) to afford the compound as a dark yellow solid.
Yield: 88%. TLC (cyclohexane/EtOAc 6:4): Rf: 0.23. Mp: 171–173 ◦C. 1H-NMR (300 MHz, CD3OD):
δ 6.93–6.91 (m, 2H, ArH), 6.84–6.81 (m, 2H, ArH) ppm. 13C-NMR (75 MHz, CD3OD): δ 129.9, 121.5,
110.2 ppm. Anal. calcd (%) for C6H6N2O2S: C, 42.34; H, 3.55; N, 16.46; S, 18.84; found: C, 41.98; H,
3.59; N, 16.35; S, 18.75.
5-Methyl-1H,3H-2,1,3-benzothiadiazole-2,2-dioxide, 1b
4-methylbenzene-1,2-diamine was reacted for 1.5 h using Procedure A; the crude residue was
purified by flash column chromatography (DCM/MeOH 98:2) to give a dark red solid. Yield: 55%.
TLC (DCM/MeOH 9:1): Rf: 0.54. Mp: 157 ◦C. 1H-NMR (300 MHz, CD3OD): δ 6.73–6.66 (m, 3H, ArH),
2.28 (s, 3H, CH3) ppm. 13C-NMR (75 MHz, CD3OD): δ 131.6, 130.1, 127.5, 121.8, 110.8, 110.2, 19.9 ppm.
Anal. calcd (%) for C7H8N2O2S: C, 45.64; H, 4.38; N, 15.21; S, 17.41; found: C, 45.11; H, 4.51; N, 14.96;
S, 17.25.
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5-(Trifluoromethyl)-1H,3H-2,1,3-benzothiadiazole-2,2-dioxide, 1c
4-(trifluoromethyl)benzene-1,2-diamine was reacted for 1.5 h using Procedure A; the purification
was performed by flash column chromatography (DCM/MeOH 9:1) to give a white solid. Yield: 66%.
TLC (DCM/MeOH 9:1): Rf: 0.19. Mp: 143 ◦C. 1H-NMR (300 MHz, CD3OD): δ 7.23 (dd, J = 8.2, 2.0 Hz,
1H, ArH), 7.06 (d, J = 2.0 Hz, 1H, ArH), 6.94 (d, J = 8.2 Hz, 1H, ArH) ppm. 13C-NMR (75 MHz, CD3OD):
δ 132.61, 129.65, 123.38, 123.06, 123.00, 118.66 (q, J = 4.2 Hz), 109.34, 106.41 (q, J = 4.2 Hz) ppm. Anal.
calcd (%) for C7H5F3N2O2S: C, 35.30; H, 2.12; N, 11.76; O, 13.43; S, 13.46; found: C, 35.61; H, 2.17; N,
11.94; S, 13.78.
5-Nitro-1H,3H-2,1,3-benzothiadiazole-2,2-dioxide, 1d
4-nitrobenzene-1,2-diamine was reacted for 1.5 h using Procedure A; the residue was purified by
flash column chromatography (DCM/MeOH 9:1) to give a red solid. Yield: 50%. TLC (DCM/MeOH
9:1): Rf: 0.15. Mp: 190 ◦C. 1H-NMR (300 MHz, CD3OD): δ 7.66 (dd, J = 8.7, 2.5 Hz, 1H, ArH), 7.38 (d,
J = 2.5 Hz, 1H, ArH), 6.53 (d, J = 8.7 Hz, 1H, ArH) ppm. 13C-NMR (75 MHz, CD3OD): δ 144.2, 140.1,
133.4, 119.6, 108.9, 104.3 ppm. Anal. calcd (%) for C6H5N3O4S: C, 33.49; H, 2.34; N, 19.53; O, 29.74; S,
14.90; found: C, 33.74; H, 2.38; N, 19.41; S, 14.51.
5-Chloro-N-[(2,4-dimethoxyphenyl)methyl]-2-nitroaniline, 7
Procedure B: A mixture of 2,4-dichloro-1-nitrobenzene (191 mg, 1 mmol), 2,4-dimethoxybenzylamine
(334 mg, 2 mmol), and isopropanol (2 mL) was heated at reflux for 16 h. After cooling, the reaction
was diluted with H2O (4 mL) and extracted with EtOAc (2 × 4 mL). The collected organic layers were
washed with 0.5 M HCl (1 × 5 mL) and then dried over anhydrous Na2SO4, filtered, and concentrated
in vacuo. The crude residue was purified by recrystallization from EtOH to obtain intermediate 7 as an
orange solid. Yield: 60%. TLC (hexane/EtOAc 85:15): Rf: 0.36. Mp: 107–109 ◦C. 1H-NMR (300 MHz,
CDCl3): δ 8.44 (br s, 1H, NH), 8.13 (d, J = 9.1 Hz, 1H, ArH), 7.18 (d, J = 8.2 Hz, 1H, ArH), 6.96 (d,
J = 2.2 Hz, 1H, ArH), 6.60 (dd, J = 9.1, 2.2 Hz, 1H, ArH), 6.53 (d, J = 2.4, 1H, ArH), 6.49 (dd, J = 8.2,
2.4 Hz, 1H, ArH), 4.44 (d, J = 5.7 Hz, 2H, CH2), 3.89 (s, 3H, CH3), 3.84 (s, 3H, CH3) ppm. 13C-NMR
(75 MHz, CDCl3): δ 160.9, 158.4, 145.8, 142.7, 130.7, 129.6, 128.2, 117.1, 115.7, 113.6, 104.3, 98.8, 55.42,
55.41, 42.2 ppm.
5-Bromo-N-[(4-methoxyphenyl)methyl]-4-methyl-2-nitroaniline, 8
1,5-dibromo-2-methyl-4-nitrobenzene and PMB-NH2 were reacted according to Procedure B to
yield 8 as an orange solid. Yield: 95%. TLC (hexane/EtOAc 9:1): Rf: 0.28. Mp: 115–116 ◦C. 1H-NMR
(300 MHz, CD3OD): δ 8.37 (s, 1H, ArH), 8.27 (br s, 1H, NH), 7.28 (d, J = 8.7 Hz, 2H, ArH), 6.93 (d,
J = 8.7 Hz, 2H, ArH), 6.75 (s, 1H, ArH), 4.46 (d, J = 5.4 Hz, 2H, CH2), 3.84 (s, 3H, CH3), 2.37 (s, 3H,
CH3) ppm. 13C-NMR (75 MHz, CD3OD): δ 159.3, 147.1, 144.1, 132.0, 129.6, 128.9, 128.4, 115.4, 114.4,
110.1, 55.3, 46.7, 23.8 ppm.
5-Chloro-N1-[(2,4-dimethoxyphenyl)methyl]benzene-1,2-diamine, 9
Procedure C: Zn dust (350 mg, 5.36 mmol) and NH4Cl (46.6 mg, 0.87 mmol) were added in a
single portion to a stirred suspension of intermediate 7 (216 mg, 0.67 mmol) in MeOH/H2O 9:1 (10 mL).
The reaction was stirred at reflux for 3 h. After completion, the mixture was filtered through celite, and
the filtrate was evaporated under vacuum. The residue was diluted with H2O (6 mL) and extracted
with EtOAc (3 × 5 mL). The collected organic layers were dried over Na2SO4, filtered, and concentrated
in vacuo. The crude residue was purified by flash column chromatography (hexane/EtOAc from 7:3 to
6:4) to obtain the desired compound as a brown solid. Yield: 71%. TLC (hexane/EtOAc 7:3): Rf: 0.28.
Mp: 135–138 ◦C. 1H-NMR (300 MHz, CDCl3): δ 7.21 (d, J = 8.2 Hz, 1H, ArH), 6.71 (d, J = 2.0 Hz, 1H,
ArH), 6.65–6.62 (m, 2H, ArH), 6.52 (d, J = 2.4 Hz, 1H, ArH), 6.48 (dd, J = 8.2, 2.4 Hz, 1H, ArH), 4.22 (s,
2H, CH2), 3.86 (s, 3H, CH3), 3.83 (s, 3H, CH3), 3.48 (br s, 2H, NH2) ppm.
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5-Bromo-N1-[(4-methoxyphenyl)methyl]-4-methylbenzene-1,2-diamine, 10
The compound was obtained from 8 following Procedure C. The crude residue was purified by
flash column chromatography (hexane/EtOAc from 8:2 to 7:3) to afford a yellow solid. Yield: 71%. TLC
(hexane/EtOAc 8:2): Rf: 0.31. Mp: 147–149 ◦C. 1H-NMR (300 MHz, CDCl3): δ 7.32 (d, J = 8.8 Hz, 2H,
ArH), 6.92 (d, J = 8.8 Hz, 2H, ArH), 6.91 (s, 1H, ArH), 6.56 (s, 1H, ArH), 4.22 (s, 2H, CH2), 3.84 (s, 3H,
CH3), 3.30 (br s, 2H, NH2), 2.30 (s, 3H, CH3) ppm. 13C-NMR (75 MHz, CDCl3): δ 159.0, 137.3, 133.1,
131.1, 129.2, 129.1, 119.9, 114.1, 113.9, 112.4, 55.3, 48.1, 22.3 ppm.
6-Chloro-1-[(2,4-dimethoxyphenyl)methyl]-1H,3H-2,1,3-benzothiadiazole-2,2-dioxide, 11
Intermediate 9 was reacted for 1.5 h following Procedure A. The crude residue was purified by flash
column chromatography (hexane/EtOAc 6:4) to afford a brown oil. Yield: 55%. TLC (hexane/EtOAc
6:4): Rf: 0.21. 1H-NMR (300 MHz, CDCl3): δ 7.33 (d, J = 8.3 Hz, 1H, ArH), 6.86 (dd, J = 8.3, 2.0 Hz, 1H,
ArH), 6.80–6.73 (m, 2H, ArH), 6.53–6.44 (m, 2H, ArH), 4.82 (s, 2H, CH2), 3.91 (s, 3H, CH3), 3.82 (s, 3H,
CH3) ppm.
6-Bromo-1-[(4-methoxyphenyl)methyl]-5-methyl-1H,3H-2,1,3-benzothiadiazole-2,2-dioxide, 12
Intermediate 10 was reacted for 1.5 h following Procedure A. The purification was performed by
flash column chromatography (hexane/EtOAc 6:4) to give the desired compound as a yellow oil. Yield:
56%. TLC (hexane/EtOAc 6:4): Rf: 0.27. 1H-NMR (300 MHz, CDCl3): δ 7.39 (d, J = 8.8 Hz, 2H, ArH),
7.02 (s, 1H, ArH), 6.93 (d, J = 8.8 Hz, 2H, ArH), 6.42 (s, 1H, ArH), 4.79 (s, 2H, CH2), 3.83 (s, 3H, CH3),
2.25 (s, 3H, CH3) ppm. 13C-NMR (75 MHz, CDCl3): δ 159.6, 132.6, 130.7, 128.9, 126.0, 125.6, 115.8, 115.4,
114.4, 110.9, 55.3, 46.1, 23.0 ppm.
5-Chloro-1H,3H-2,1,3-benzothiadiazole-2,2-dioxide, 1e
Procedure D: Intermediate 11 (40 mg, 0.113 mmol) was dissolved in DCM (1 mL), and TFA (1 mL)
was added dropwise. The reaction mixture was stirred for 45 min at 40 ◦C. After the evaporation of
TFA under vacuum, MeOH was added and the white precipitate was filtered off. The filtrate was
concentrated in vacuo and purified by flash column chromatography (hexane/EtOAc 6:4) to give
product 1e as a pale pink solid. Yield: 82%. TLC (hexane/EtOAc 6:4): Rf: 0.48. Mp: 183 ◦C. 1H-NMR
(300 MHz, CD3OD): δ 6.91 (dd, J = 8.4, 2.1 Hz, 1H, ArH), 6.83 (d, J = 2.1 Hz, 1H, ArH), 6.78 (d, J = 8.4 Hz,
1H, ArH) ppm. 13C-NMR (75 MHz, CD3OD): δ 130.8, 128.4, 126.4, 121.0, 111.0, 110.1 ppm. Anal. calcd
(%) for C6H5ClN2O2S: C, 35.22; H, 2.46; N, 13.69; S, 15.67; found: C, 34.98; H, 2.49; N, 13.42; S, 15.48.
5-Bromo-6-methyl-1H,3H-2,1,3-benzothiadiazole-2,2-dioxide, 2a
The product was obtained starting from intermediate 12 following Procedure D. The crude residue
was purified by flash column chromatography (DCM/MeOH 95:5) to yield the desired compound as a
white solid. Yield: 85%. TLC (DCM/MeOH 95:5): Rf: 0.19. Mp: 185 ◦C. 1H-NMR (300 MHz, CD3OD):
δ 6.99 (s, 1H, ArH), 6.77 (s, 1H, ArH), 2.32 (s, 3H, CH3) ppm. 13C-NMR (75 MHz, CD3OD): δ 130.5,
129.5, 129.0, 115.2, 113.6, 112.0, 21.3 ppm. Anal. calcd (%) for C7H7BrN2O2S: C, 31.95; H, 2.68; N, 10.65;
S, 12.19; found: C, 32.08; H, 2.75; N, 10.29; S, 12.31.
1,3-Bis[(4-methoxyphenyl)methyl]-5-nitro-2,1,3-benzothiadiazole-2,2-dioxide, 13
Procedure E: To a stirred solution of 1d (140 mg, 0.65 mmol) in dry DMF (2 mL), dried K2CO3
(179.7 mg, 1.3 mmol) and PMB-Br (313.6 mg, 1.56 mmol) were added. The mixture was stirred at
80 ◦C for 2 h and then cooled to room temperature, diluted with H2O (6 mL), and extracted with
EtOAc (2 × 5 mL). The collected organic layers were dried over anhydrous Na2SO4, filtered, and
evaporated in vacuo. The crude residue was purified by flash chromatography (hexane/EtOAc 8:2) to
give intermediate 13 as a yellow solid. Yield: 90%. TLC (hexane/EtOAc 8:2): Rf: 0.28. Mp: 116 ◦C.
1H-NMR (300 MHz, CDCl3): δ 7.71 (dd, J = 8.8, 2.2 Hz, 1H, ArH), 7.38–7.33 (m, 3H, ArH), 7.30 (d,
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J = 8.8 Hz, 2H, ArH), 6.85 (d, J = 8.8 Hz, 2H, ArH), 6.83 (d, J = 8.8 Hz, 2H, ArH), 6.50 (d, J = 8.8 Hz,
1H, ArH), 4.86 (s, 4H, CH2), 3.73 (s, 3H, CH3), 3.72 (s, 3H, CH3) ppm. 13C-NMR (75 MHz, CDCl3): δ
159.88, 159.86, 142.1, 133.7, 129.3, 129.1, 128.7, 124.96, 124.93, 118.4, 114.59, 114.56, 107.3, 103.7, 55.3,
46.5, 46.2 ppm.
5-Amino-1,3-bis[(4-methoxyphenyl)methyl]-2,1,3-benzothiadiazole-2,2-dioxide, 14
Intermediate 13 was reacted for 4 h following Procedure C. The crude residue was purified by
flash column chromatography (cyclohexane/EtOAc from 1:1 to 4:6) to give the desired product as a
yellow oil. Yield: 46%. TLC (cyclohexane/EtOAc 6:4): Rf: 0.23. 1H-NMR (300 MHz, CDCl3): δ 7.32–7.25
(m, 4H, ArH), 6.84–6.77 (m, 4H, ArH), 6.25 (d, J = 8.3 Hz, 1H, ArH), 6.01 (dd, J = 8.3, 2.3 Hz, 1H, ArH),
5.85 (d, J = 2.3 Hz, 1H, ArH), 4.68 (s, 2H, CH2), 4.67 (s, 2H, CH2), 3.71 (s, 6H, CH3), 3.31 (br s, 2H, NH2)
ppm. 13C-NMR (75 MHz, CDCl3): δ 159.40, 159.39, 141.7, 130.8, 129.0, 128.8, 127.0, 126.7, 121.9, 114.3,
114.2, 110.2, 107.5, 97.3, 55.29, 55.28, 47.2, 46.1 ppm.
N-{1,3-Bis[(4-methoxyphenyl)methyl]-2,2-dioxo-2,1,3-benzothiadiazol-5-yl}acetamide, 15
Intermediate 14 (114.9 mg, 0.27 mmol) was dissolved in acetone (2 mL), and the mixture was
cooled to 0 ◦C in an ice bath. Acetic anhydride (41.3 mg, 0.41 mmol) was added dropwise, and the
solution was stirred at room temperature for 2 h. After completion, the solvent was removed in vacuo
and the residue was diluted with 1 M NaOH and extracted with EtOAc (2 × 3 mL). The collected
organic layers were dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude
residue was purified by flash column chromatography (cyclohexane/EtOAc from 5:5 to 4:6) to obtain
intermediate 15 as a dark green solid. Yield: 98%. TLC (cyclohexane/EtOAc 4:6): Rf: 0.22. Mp: 153 ◦C.
1H-NMR (300 MHz, CDCl3): δ 7.43–7.37 (m, 5H, ArH and NH), 7.11 (d, J = 2.1 Hz, 1H, ArH), 6.94–6.85
(m, 4H, ArH), 6.73 (dd, J = 8.4, 2.1 Hz, 1H, ArH), 6.44 (d, J = 8.4 Hz, 1H, ArH), 4.82 (s, 2H, CH2), 4.81 (s,
2H, CH2), 3.81 (s, 3H, OCH3), 3.78 (s, 3H, OCH3), 2.06 (s, 3H, CH3) ppm. 13C-NMR (75 MHz, CDCl3):
δ 168.4, 159.49, 159.47, 132.4, 129.5, 129.2, 129.0, 126.4, 126.3, 125.7, 114.3, 112.8, 108.7, 101.8, 55.29, 55.25,
46.4, 46.1, 24.3 ppm.
N-(2,2-Dioxo-1H,3H-2,1,3-benzothiadiazol-5-yl)acetamide, 1f
Intermediate 15 was reacted for 8 h at room temperature following Procedure D. The crude residue
was purified by flash column chromatography (DCM/MeOH from 95:5 to 9:1) to afford a white foam.
Yield: 52%. TLC (DCM/MeOH 85:15): Rf: 0.37. 1H-NMR (300 MHz, CD3OD): δ 7.14 (d, J = 2.1 Hz,
1H, ArH), 6.83 (dd, J = 8.4, 2.1 Hz, 1H, ArH), 6.64 (d, J = 8.4 Hz, 1H, ArH), 1.99 (s, 3H, CH3) ppm.
13C-NMR (75 MHz, CD3OD): δ 170.0, 133.0, 130.3, 126.2, 113.1, 110.3, 103.3, 22.2 ppm. Anal. calcd (%)
for C8H9N3O3S: C, 42.28; H, 3.99; N, 18.49; O, 21.12; S, 14.11; found: C, 42.37; H, 4.02; N, 18.65; S, 14.32.
4-Bromo-N-[(4-methoxyphenyl)methyl]-2-nitroaniline, 16
A mixture of 2,5-dibromo-nitrobenzene (200 mg, 0.71 mmol) and PMB-NH2 (293 mg, 2.14 mmol)
was heated at 160 ◦C for 8 h. After cooling, the reaction was diluted with H2O (4 mL) and extracted
with EtOAc (2 × 4 mL). The collected organic layers were washed with 0.5 M HCl (1 × 8 mL) and then
dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude residue was purified by
flash chromatography (cyclohexane/EtOAc 8:2) to afford the desired compound as an orange solid.
Yield: 95%. TLC (cyclohexane/EtOAc 9:1): Rf: 0.35. Mp: 121 ◦C. 1H-NMR (300 MHz, CDCl3): δ 8.25
(br s, 1H, NH), 8.23 (d, J = 2.4 Hz, 1H, ArH), 7.35 (dd, J = 9.2, 2.4 Hz, 1H, ArH), 7.16 (d, J = 8.8 Hz, 2H,
ArH), 6.81 (d, J = 8.8 Hz, 2H, ArH), 6.65 (d, J = 9.2 Hz, 1H, ArH), 4.37 (d, J = 5.5 Hz, 2H, CH2), 3.72 (s,
3H, CH3) ppm. 13C-NMR (75 MHz, CDCl3): δ 159.3, 144.1, 138.9, 132.5, 128.9, 128.7, 128.4, 116.0, 114.4,
106.8, 55.3, 46.7 ppm.
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4-Bromo-N1-[(4-methoxyphenyl)methyl]benzene-1,2-diamine, 17
Compound 16 was reacted according to Procedure C; the resulting crude residue was purified by
flash column chromatography (cyclohexane/EtOAc from 7.5:2.5 to 7:3) to afford the desired product
as a pale yellow solid. Yield: 54%. TLC (cyclohexane/EtOAc 7:3): Rf: 0.36. Mp: 116 ◦C. 1H-NMR
(300 MHz, CDCl3): δ 7.32 (d, J = 8.8 Hz, 2H, ArH), 6.96–6.88 (m, 3H, ArH), 6.86 (d, J = 2.4 Hz, 1H, ArH),
6.55 (d, J = 8.4 Hz, 1H, ArH), 4.23 (s, 2H, CH2), 3.84 (s, 3H, CH3), 3.57 (br s, 1H, NH), 3.40 (br s, 2H,
NH2) ppm. 13C-NMR (75 MHz, CDCl3): δ 159.0, 136.6, 135.8, 131.0, 129.0, 123.0, 118.9, 114.1, 113.3,
110.7, 55.3, 48.1 ppm.
5-Bromo-1-[(4-methoxyphenyl)methyl]-3H-2,1,3-benzothiadiazole-2,2-dioxide, 18
Intermediate 17 was reacted for 2 h following Procedure A. The crude residue was purified by
flash column chromatography (cyclohexane/EtOAc from 6:4 to 1:1), to afford compound 18 as a red
solid. Yield: 60%. TLC (cyclohexane/EtOAc 6:4): Rf: 0.19. Mp: 166 ◦C. 1H-NMR (300 MHz, CDCl3): δ
7.26 (d, J = 8.8 Hz, 2H, ArH), 6.87–6.82 (m, 2H, ArH), 6.80 (d, J = 8.8 Hz, 2H, ArH), 6.28 (d, J = 8.4 Hz,
1H, ArH), 4.69 (s, 2H, CH2), 3.70 (s, 3H, CH3) ppm. 13C-NMR (75 MHz, CDCl3): δ 159.6, 129.7, 129.0,
127.8, 125.8, 125.5, 114.4, 114.3, 113.7, 110.1, 55.3, 46.0 ppm.
5-Bromo-1,3-bis[(4-methoxyphenyl)methyl]-2,1,3-benzothiadiazole-2,2-dioxide, 19
The desired product was obtained starting from 18 following Procedure E. The crude residue was
purified by flash column chromatography (cyclohexane/EtOAc 8:2) to afford a pale yellow solid. Yield:
98%. TLC (cyclohexane/EtOAc 7:3): Rf: 0.59. Mp: 134 ◦C. 1H-NMR (300 MHz, CDCl3): δ 7.48–7.36 (m,
4H, ArH), 6.98–6.84 (m, 5H, ArH), 6.70 (d, J = 1.9 Hz, 1H, ArH), 6.42 (d, J = 8.4 Hz, 1H, ArH), 4.86 (s,
4H, CH2), 3.84 (s, 3H, CH3), 3.83 (s, 3H, CH3) ppm. 13C-NMR (75 MHz, CDCl3): δ 159.7, 159.6, 130.2,
129.0, 128.1, 125.9, 125.8, 124.1, 114.5, 114.4, 113.8, 111.5, 109.7, 55.3, 46.3 ppm.
Ethyl (2E)-3-{1,3-bis[(4-methoxyphenyl)methyl]-2,2-dioxo-2,1,3-benzothiadiazol-5-yl} prop-2-enoate, 20
To a solution of intermediate 19 (200 mg, 0.41 mmol) in DMF (2.0 mL), triethylamine (0.28 mL,
2.05 mmol), ethyl acrylate (0.17 mL, 1.64 mmol), tri-o-tolylphosphine (74.8 mg, 0.25 mmol), and
tris(dibenzylideneacetone)dipalladium(0) (75.1 mg, 0.08 mmol) were added, and the mixture was
heated to 80 ◦C for 20 h. The reaction was then cooled to ambient temperature, and DMF was
evaporated. The residue was diluted with H2O (3 mL) and extracted with EtOAc (3 × 3 mL).
The collected organic layers were dried over Na2SO4, filtered, concentrated in vacuo, and purified by
flash column chromatography (cyclohexane/EtOAc 8:2) to afford the desired product as a yellow foam.
Yield: 50%. TLC (cyclohexane/EtOAc 7:3): Rf: 0.31. 1H-NMR (300 MHz, CDCl3): δ 7.39 (d, J = 16.0 Hz,
1H, CH), 7.35–7.30 (m, 4H, ArH), 6.90 (dd, J = 8.2, 1.6 Hz, 1H, ArH), 6.87–6.80 (m, 4H, ArH), 6.62 (d,
J = 1.6 Hz, 1H, ArH), 6.46 (d, J = 8.2 Hz, 1H, ArH), 6.04 (d, J = 16.0 Hz, 1H, CH), 4.80 (s, 2H, CH2),
4.79 (s, 2H, CH2), 4.14 (q, J = 7.1 Hz, 2H, OCH2) 3.74 (s, 3H, CH3), 3.72 (s, 3H, CH3), 1.23 (t, J = 7.1 Hz,
3H, CH3). 13C-NMR (75 MHz, CDCl3): δ 167.0, 159.63, 159,62, 144.1, 130.7, 129.5, 128.99, 128.95, 128.2,
125.95, 125.93, 122.8, 116.5, 114.5, 114.4, 108.4, 106.9, 60.5, 55.3, 46.3, 46.2, 14.3 ppm.
(2E)-3-{1,3-Bis[(4-methoxyphenyl)methyl]-2,2-dioxo-2,1,3-benzothiadiazol-5-yl} prop-2-enoic acid, 21
To a solution of intermediate 20 (53.4 mg, 0.105 mmol) in MeOH (2 mL), 3 M NaOH (1 mL) was
added, and the mixture was stirred at 80 ◦C for 3 h. After cooling, MeOH was evaporated under
vacuum and 2 M HCl (1.5 mL) was added until pH 2. Extraction with EtOAc (3 × 3 mL) was carried
out, and the collected organic layers were dried over Na2SO4, filtered, and evaporated in vacuo to
afford the acid 21 as a pale yellow solid, which was used in the next step for further purification. Yield:
quantitative. TLC (DCM/MeOH 95:5): Rf: 0.26. Mp: 125–127 ◦C. 1H-NMR (300 MHz, CDCl3): δ 7.55
(d, J = 16 Hz, 1H, CH), 7.47–7.34 (m, 4H, ArH), 7.00 (dd, J = 8.1, 1.6 Hz, 1H, ArH), 6.97–6.84 (m, 4H,
ArH), 6.70 (d, J = 1.6 Hz, 1H, ArH), 6.54 (d, J = 8.1 Hz, 1H, ArH), 6.11 (d, J = 16 Hz, 1H, CH), 4.89
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(s, 4H, CH2), 3.82 (s, 3H, CH3), 3.80 (s, 3H, CH3) ppm. 13C-NMR (75 MHz, CDCl3): δ 172.35, 159.85,
146.87, 131.29, 129.71, 129.21, 127.5, 126.04, 123.58, 115.33, 114.66, 108.64, 107.23, 55.45, 46.40 ppm.
(2E)-3-{1,3-Bis[(4-methoxyphenyl)methyl]-2,2-dioxo-2,1,3-benzothiadiazol-5-yl}-N-(3-methylbutyl)prop-
2-enamide, 22
Procedure F: To a mixture of 21 (50.5 mg, 0.105 mmol) in DCM (1 mL), isopentylamine (13.7 mg, 0.15
mmol), N,N-diisopropylethylamine (DIPEA, 27.1 mg, 0.21 mmol), and HATU (47.9 mg, 0.126 mmol)
were added. The reaction mixture was stirred at room temperature for 16 h; after completion, the
solvent was evaporated and the residue was diluted with H2O (3 mL) and extracted with EtOAc
(3 × 3 mL). The organic layers were washed with 1 M HCl (1 × 3 mL) and then dried over Na2SO4,
filtered, and concentrated in vacuo. Purification by flash column chromatography (DCM/MeOH 95:5)
afforded compound 22 as a yellow oil. Yield: 62%. TLC (DCM/EtOAc 9:1): Rf: 0.55. 1H-NMR (300
MHz, CDCl3): δ 7.45–7.36 (m, 5H, ArH), 7.00–6.87 (m, 5H, ArH, CH), 6.67 (d, J = 1.6 Hz, 1H, ArH), 6.53
(d, J = 8.2 Hz, 1H, ArH), 6.09 (d, J = 15.5 Hz, 1H, CH), 5.62 (br t, J = 5.7 Hz, 1H, NH), 4.87 (s, 4H, CH2),
3.82 (s, 3H, OCH3), 3.81 (s, 3H, OCH3), 3.40–3.35 (m, 2H, CH2), 1.74–1.56 (m, 1H, CH), 1.47–1.41 (m,
2H, CH2), 0.91 (d, J = 6.6 Hz, 6H, CH3) ppm. 13C-NMR (75 MHz, CDCl3): δ 165.8, 159.58, 159.57, 140.3,
130.1, 129.5, 128.99, 128.92, 128.7, 128.6, 126.1, 126.0, 122.0, 119.3, 114.43, 114.37, 114.0, 108.5, 107.1, 55.3,
46.23, 46.17, 38.6, 38.0, 25.9, 22.4 ppm.
(2E)-3-{1,3-Bis[(4-methoxyphenyl)methyl]-2,2-dioxo-2,1,3-benzothiadiazol-5-yl}-N-phenylprop-2-
enamide, 23
To a stirred solution of 21 (50 mg, 0.104 mmol) in DCM (2.5 mL), aniline (0.03 mL, 0.32 mmol),
TBTU (46 mg, 0.142 mmol), and N-methylmorpholine (up to pH 7) were added. The reaction mixture
was stirred at room temperature for 24 h. After completion, the product was extracted with DCM
(3 × 3 mL), and the organic layer was washed with 1 M HCl (1 × 3 mL) and then with a saturated
solution of NaHCO3 (1 × 3 mL) and finally with brine (1 × 3 mL). The organic phase was dried over
anhydrous Na2SO4, filtered, and concentrated in vacuo. Purification by flash column chromatography
(cyclohexane/EtOAc 7:3) yielded intermediate 23 as a white solid. Yield: 69%. TLC (cyclohexane/EtOAc
6:4): Rf: 0.47. Mp: 180–182 ◦C. 1H-NMR (300 MHz, CDCl3): δ 7.57 (br s, 1H, NH), 7.52 (d, J = 15.4 Hz,
1H, CH), 7.43–7.27 (m, 8H, ArH), 7.11 (t, J = 7.4, 1H, ArH), 6.98 (dd, J = 8.1, 1.6 Hz, 1H, ArH), 6.96–6.87
(m, 4H, ArH), 6.67 (d, J = 1.6 Hz, 1H, ArH), 6.53 (d, J = 8.1 Hz, 1H, ArH), 6.21 (d, J = 15.4 Hz, 1H, CH),
4.87 (s, 4H, CH2), 3.81 (s, 3H, CH3), 3.80 (s, 3H, CH3) ppm.
3-(2,2-Dioxo-1H,3H-2,1,3-benzothiadiazol-5-yl)-N-(3-methylbutyl)propanamide, 1g
Procedure G: Intermediate 22 (100 mg, 0.182 mmol) was dissolved in EtOH (10 mL), and the
solution was degassed by bubbling Ar for 10 min. Pd/C (10% w/w) was then added, and the mixture
was stirred at room temperature under an H2 atmosphere (3 atm) for 48 h. After completion, the
reaction mixture was filtered through celite, and the filtrate was evaporated under vacuum. The crude
residue was purified by flash column chromatography (DCM/MeOH 95:5 to 9:1) to obtain product
1g as a pale brown oil. Yield: 3%. TLC (DCM/MeOH 9:1): Rf: 0.41. 1H-NMR (300 MHz, CD3OD): δ
6.78–6.55 (m, 3H, ArH), 3.12 (t, J = 7.5 Hz, 2H, CH2), 2.82 (t, J = 7.5 Hz, 2H, CH2), 2.41 (t, J = 7.5 Hz, 2H,
CH2), 1.55–1.37 (m, 1H, CH), 1.35–1.18 (m, 2H, CH2), 0.86 (d, J = 6.6 Hz, 6H, CH3) ppm. 13C-NMR
(75 MHz, CDCl3): δ 173.5, 134.6, 130.2, 128.2, 121.2, 110.2, 37.8, 37.1, 31.4, 25.2, 21.3 ppm. Anal. calcd
(%) for C14H21N3O3S: C, 54.00; H, 6.80; N, 13.49; S, 10.30; found: C, 54.08; H, 6.95; N, 13.27; S, 10.41.
3-(2,2-Dioxo-1H,3H-2,1,3-benzothiadiazol-5-yl)-N-phenylpropanamide, 1h
The compound was obtained by reacting 23 at 50 ◦C for 5 h following Procedure G. The crude
residue was purified by flash column chromatography (DCM/MeOH 9:1) to afford a white solid. Yield:
10%. TLC (DCM/MeOH 9:1): Rf: 0.40. Mp: 192–197 ◦C. 1H-NMR (300 MHz, CD3OD): δ 7.51–7.45 (m,
2H, ArH), 7.33–7.22 (m, 2H, ArH), 7.13–6.99 (m, 1H, ArH), 6.80 (dd, J = 8.1, 1.7 Hz, 1H, ArH), 6.76–6.70
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(m, 2H, ArH) 2.93 (t, J = 7.6 Hz, 2H, CH2), 2.61 (t, J = 7.6 Hz, 2H, CH2) ppm. 13C-NMR (75 MHz,
CD3OD): δ 172.1, 138.3, 134.8, 130.1, 128.3, 128.1, 123.8, 121.3, 120.0, 110.3, 38.7, 31.2 ppm. Anal. calcd
(%) for C15H15N3O3S: C, 56.77; H, 4.76; N, 13.24; S, 10.10; found: C, 56.89; H, 4.81; N, 13.16; S, 10.14.
1,3-Bis[(4-methoxyphenyl)methyl]-5-phenyl-2,1,3-benzothiadiazole-2,2-dioxide, 24
A flask was charged with 19 (70 mg, 0.14 mmol), Na2CO3 (30 mg, 0.28 mmol), phenylboronic acid
(18 mg, 0.15 mmol), and tetrakis(triphenylphosphine)palladium(0) (32 mg, 0.028 mmol) under an Ar
atmosphere. Then, 1,4-dioxane (3 mL) and a drop of H2O were added. The resulting mixture was
heated to reflux for 5 h. After completion, the reaction was cooled to room temperature, H2O was
added (3 mL), and the mixture was extracted with EtOAc (3 × 2 mL). The collected organic layers
were dried over Na2SO4, filtered, and evaporated in vacuo. The residue was purified by flash column
chromatography (cyclohexane/EtOAc 7:3) to afford the desired product as a pale-yellow oil. Yield:
68%. TLC (cyclohexane/EtOAc 7:3): Rf: 0.50. 1H-NMR (300 MHz, CDCl3): δ 7.38–7.32 (m, 4H, ArH),
7.30–7.23 (m, 4H, ArH, partially hidden by solvent peak), 7.22–7.17 (m, 1H, ArH), 6.93 (dd, J = 8.1,
1.8 Hz, 1H, ArH), 6.87–6.80 (m, 4H, ArH), 6.70 (d, J = 1.8 Hz, 1H, ArH), 6.52 (d, J = 8.1 Hz, 1H, ArH),
4.83 (s, 2H, CH2), 4.80 (s, 2H, CH2), 3.72 (s, 3H, CH3), 3.71 (s, 3H, CH3) ppm. 13C-NMR (75 MHz,
CDCl3): δ 159.5, 140.7, 135.2, 129.7, 129.04, 129.02, 128.97, 128.8, 128.6, 127.1, 126.8, 126.4, 120.4, 114.37,
114.35, 114.31, 108.8, 107.4, 55.3, 46.33, 46.29 ppm.
5-Phenyl-1H,3H-2,1,3-benzothiadiazole-2,2-dioxide, 1i
Intermediate 24 was reacted for 3 h at room temperature following Procedure D. The crude residue
was purified by flash column chromatography (cyclohexane/EtOAc 6:4) to afford a white solid. Yield:
20%. TLC (cyclohexane/EtOAc 6:4): Rf: 0.42. Mp: 180–185 ◦C. 1H-NMR (300 MHz, CD3OD): δ 7.47–7.38
(m, 2H, ArH), 7.33–7.26 (m, 2H, ArH), 7.24–7.14 (m, 1H, ArH), 7.07 (dd, J = 8.1, 1.8 Hz, 1H, ArH), 6.96
(d, J = 1.8 Hz, 1H, ArH), 6.78 (d, J = 8.1 Hz, 1H, ArH) ppm. Anal. calcd (%) for C12H10N2O2S: C, 58.52;
H, 4.09; N, 11.37; S, 13.02; found: C, 58.48; H, 4.11; N, 11.26; S, 13.18.
1,3-Dibenzyl-2,1,3-benzothiadiazole-2,2-dioxide, 3
The compound was obtained starting from 1a and benzyl bromide following Procedure E.
The crude residue was purified by flash column chromatography (hexane/EtOAc 9:1) to afford the
desired product as a white solid. Yield: 90%. TLC (hexane/EtOAc 7:3): Rf: 0.81. Mp: 134 ◦C. 1H-NMR
(300 MHz, CDCl3): δ 7.56–7.48 (m, 4H, ArH), 7.45–7.39 (m, 4H, ArH), 7.38–7.32 (m, 2H, ArH), 6.86–6.81
(m, 2H, ArH), 6.59–6.54 (m, 2H, ArH), 4.96 (s, 4H, CH2) ppm. 13C-NMR (75 MHz, CDCl3): δ 134.6,
129.3, 128.9, 128.1, 127.5, 121.6, 108.5, 46.7 ppm. Anal. calcd (%) for C20H18N2O2S: C, 68.55; H, 5.18; N,
7.99; S, 9.15; found: C, 68.63; H, 5.17; N, 8.13; S, 9.17.
1,3,5-Trimethyl-2,1,3-benzothiadiazole-2,2-dioxide, 2b
In a flame-dried flask, 1b (50 mg, 0.27 mmol) was solubilized in dry DMF under an Ar atmosphere;
oven-dried K2CO3 (111.9 mg, 0.81 mmol) was then added, and the mixture was stirred for 30 min.
After cooling to 0 ◦C on an ice bath, CH3I (0.050 mL, 0.81 mmol) was added dropwise, and the
reaction was heated at 80 ◦C for 2 h. After completion, DMF was removed under reduced pressure
and the remaining mixture was diluted with 1 M HCl (3 mL), and then the product was extracted
with EtOAc (3 × 3 mL). The organic fractions were combined, dried over anhydrous Na2SO4, filtered,
and evaporated under vacuum. The crude residue was purified by flash column chromatography
(hexane/EtOAc 8:2) to afford product 2b as a white foam. Yield: 87%. TLC (hexane/EtOAc 6:4): Rf:
0.78. 1H-NMR (300 MHz, CDCl3): δ 6.81 (dd, J = 8.0, 1.5 Hz, 1H, ArH), 6.64 (d, J = 8.0 Hz, 1H, ArH),
6.58 (d, J = 1.5 Hz, 1H, ArH), 3.28 (s, 3H, NCH3), 3.27 (s, 3H, NCH3), 2.36 (s, 3H, CH3) ppm. 13C-NMR
(75 MHz, CDCl3): δ 131.7, 130.4, 128.2, 122.0, 108.7, 107.7, 28.2, 27.9, 21.4 ppm. Anal. calcd (%) for
C9H12N2O2S: C, 50.92; H, 5.70; N, 13.20; S, 15.11; found: C, 50.78; H, 5.63; N, 13.28; S, 15.17.
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N-[(2,4-Dimethoxyphenyl)methyl]-2-nitroaniline, 25
In a two-neck flask, a solution of 1-chloro-2-nitrobenzene (200 mg, 1.27 mmol) and DMB-NH2
(637 mg, 3.8 mmol) in EtOH was heated overnight at 100 ◦C. After completion, EtOH was evaporated
under vacuum, and the residue was dissolved in EtOAc and washed with 1 M HCl (1 × 3 mL).
The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated in vacuo. The crude
residue was purified by flash column chromatography (hexane/EtOAc 8:2) to give the desired compound
as an orange solid. Yield: 80%. TLC (hexane/EtOAc 8:2): Rf: 0.32. Mp: 85–87 ◦C. 1H-NMR (300 MHz,
CDCl3): δ 8.43 (br s, 1H, NH), 8.20 (dd, J = 8.7, 1.7 Hz, 1H, ArH), 7.43–7.39 (m, 1H, ArH), 7.17 (d,
J = 8.4 Hz, 1H, ArH), 6.91 (dd, J = 8.7, 1.7 Hz, 1H, ArH), 6.67–6.62 (m, 1H, ArH), 6.52 (d, J = 2.4, 1H,
ArH), 6.46 (dd, J = 8.4, 2.4 Hz, 1H, ArH), 4.48 (d, J = 5.6 Hz, 2H, CH2), 3.88 (s, 3H, CH3), 3.83 (s, 3H,
CH3) ppm.
N1-[(2,4-Dimethoxyphenyl)methyl]benzene-1,2-diamine, 26
Intermediate 25 was reacted for 1 h at reflux following Procedure C. The crude residue was
purified by flash column chromatography (cyclohexane/EtOAc from 7:3 to 6:4) to afford a yellow solid.
Yield: 73%. TLC (cyclohexane/EtOAc 6:4): Rf: 0.37. Mp: 107–112 ◦C. 1H-NMR (300 MHz, CDCl3): δ
7.27 (d, J = 8.2 Hz, 1H, ArH), 6.92–6.82 (m, 1H, ArH), 6.78 (d, J = 8.4 Hz, 1H, ArH), 6.77–6.73 (m, 2H,
ArH), 6.56 (d, J = 2.4 Hz, 1H, ArH), 6.51 (dd, J = 8.2, 2.4 Hz, 1H, ArH), 4.30 (s, 2H, CH2), 3.88 (s, 3H,
CH3), 3.86 (s, 3H, CH3), 3.52 (br s, 2H, NH2) ppm. 13C-NMR (75 MHz, CDCl3): δ 160.3, 158.6, 137.9,
134.8, 130.0, 120.5, 120.0, 118.8, 116.3, 112.7, 104.1, 98.7, 55.42, 55.40, 43.7 ppm.
1-[(2,4-Dimethoxyphenyl)methyl]-3H-2,1,3-benzothiadiazole-2,2-dioxide, 27
The product was obtained by reacting 26 for 2 h at 160 ◦C following Procedure A. The crude
residue was purified by flash column chromatography (cyclohexane/EtOAc 6:4) to give the desired
compound as a sticky yellow solid. Yield: 78%. TLC (cyclohexane/EtOAc 1:1): Rf: 0.31. 1H-NMR
(300 MHz, CDCl3): δ 7.33 (d, J = 8.4 Hz, 1H, ArH), 7.03–6.84 (m, 3H, ArH), 6.72 (dd, J = 7.3, 1.1 Hz, 1H,
ArH), 6.52 (d, J = 2.4 Hz, 1H, ArH), 6.48 (dd, J = 8.4, 2.4 Hz, 1H, ArH), 4.86 (s, 2H, CH2), 3.90 (s, 3H,
CH3), 3.82 (s, 3H, CH3) ppm.
Ethyl 2-{3-[(2,4-dimethoxyphenyl)methyl]-2,2-dioxo-2,1,3-benzothiadiazol-1-yl}acetate, 28
Intermediate 27 (100 mg, 0.31 mmol), K2CO3 (55.74 mg, 0.403 mmol), and ethyl bromoacetate
(62.8 mg, 0.38 mmol) were reacted according to Procedure E. The crude residue was purified by flash
column chromatography (hexane/EtOAc 7:3) to afford the desired compound as a yellow solid. Yield:
90%. TLC (hexane/EtOAc 6:4): Rf: 0.52. Mp: 128–132 ◦C. 1H-NMR (300 MHz, CDCl3): δ 7.34 (d,
J = 8.4 Hz, 1H, ArH), 6.97–6.90 (m, 2H, ArH), 6.75–6.67 (m, 2H, ArH), 6.51 (d, J = 2.4 Hz, 1H, ArH),
6.48 (dd, J = 8.4, 2.4 Hz, 1H, ArH), 4.90 (s, 2H, CH2), 4.47 (s, 2H, CH2), 4.29 (q, J = 7.1 Hz, 2H, OCH2),
3.90 (s, 3H, OCH3), 3.82 (s, 3H, OCH3), 1.30 (t, J = 7.1 Hz, 3H, CH3) ppm.
2-{3-[(2,4-Dimethoxyphenyl)methyl]-2,2-dioxo-2,1,3-benzothiadiazol-1-yl} acetic acid, 29
To a solution of intermediate 28 (63 mg, 0.16mmol) in MeOH (2 mL), 2% aqueous K2CO3 (1 mL)
was added, and the mixture was stirred at 50 ◦C for 2 h. After cooling, MeOH was evaporated under
vacuum, and 2 M HCl (1.5 mL) was added until it reached pH 4. Extraction with EtOAc (3 × 3 mL)
was carried out, and the collected organic layers were dried over anhydrous Na2SO4, filtered, and
evaporated in vacuo to obtain the acid 29 as a yellow oil, which was used in the next step without any
further purification. Yield: quantitative. TLC (DCM/MeOH 9:1): Rf: 0.10. 1H-NMR (300 MHz, CDCl3):
δ 9.91 (br s, 1H, COOH), 7.32 (d, J = 8.4 Hz, 1H, ArH), 6.99–6.91 (m, 2H, ArH), 6.79–6.68 (m, 2H, ArH),
6.51 (d, J = 2.4 Hz, 1H, ArH), 6.47 (dd, J = 8.4, 2.4 Hz, 1H, ArH), 4.90 (s, 2H, CH2), 4.52 (s, 2H, CH2),
3.89 (s, 3H, CH3), 3.81 (s, 3H, CH3) ppm.
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2-{3-[(2,4-Dimethoxyphenyl)methyl]-2,2-dioxo-2,1,3-benzothiadiazol-1-yl}-N-phenethylacetamide, 30
Intermediate 29 and 2-phenylethanamine were reacted for 24 h following Procedure F. The crude
residue was purified by flash column chromatography (hexane/EtOAc 6:4) to afford the desired
compound as a yellow oil. Yield: 47%. TLC (DCM/MeOH 95:5): Rf: 0.83. 1H-NMR (300 MHz, CDCl3):
δ 7.30 (d, J = 8.4 Hz, 1H, ArH), 7.20–7.16 (m, 3H, ArH), 7.10–7.03 (m, 2H, ArH), 7.01–6.96 (m, 2H, ArH),
6.85–6.78 (m, 1H, ArH), 6.70–6.64 (m, 1H, ArH), 6.63 (br t, J = 5.8 Hz, 1H, NH), 6.53 (d, J = 2.4 Hz, 1H,
ArH), 6.50 (dd, J = 8.4, 2.4 Hz, 1H, ArH), 4.88 (s, 2H, CH2), 4.34 (s, 2H, CH2), 3.92 (s, 3H, CH3), 3.83 (s,
3H, CH3), 3.56 (td, J = 7.0, 5.8 Hz, 2H, NHCH2), 2.78 (t, J = 7.0 Hz, 2H, CH2CH2) ppm.
2-(2,2-Dioxo-3H-2,1,3-benzothiadiazol-1-yl)-N-(2-phenylethyl)acetamide, 4
Intermediate 30 was reacted according to Procedure D. The crude residue was purified by flash
column chromatography (DCM/MeOH 95:5) to give the product as a white solid. Yield: 88%. TLC
(DCM/MeOH 9:1): Rf: 0.41. Mp: 172 ◦C. 1H-NMR (300 MHz, CD3OD): δ 8.06 (t, J = 5.9 Hz, 1H,
NH), 7.29–7.23 (m, 2H, ArH), 7.22–7.16 (m, 3H, ArH), 7.00–6.94 (m, 2H, ArH), 6.92–6.84 (m, 1H, ArH),
6.70–6.58 (m, 1H, ArH), 4.27 (s, 2H, CH2), 3.49 (td, J = 7.2, 5.9 Hz, 2H, NHCH2), 2.81 (t, J = 7.2 Hz, 2H,
CH2CH2) ppm. 13C-NMR (75 MHz, CD3OD): δ 167.6, 138.8, 131.3, 128.5, 128.1, 126.0, 121.9, 121.7,
110.5, 108.2, 44.2, 40.6, 35.0 ppm. Anal. calcd (%) for C16H17N3O3S: C, 57.99; H, 5.17; N, 12.68; S, 9.68;
found: C, 58.05; H, 5.21; N, 12.49; S, 9.72.
2,3-Dihydro-1H-1,3-benzodiazol-2-one, 5
In a two-neck flamed-dried flask, a solution of o-phenylenediamine (30 mg, 0.28 mmol) and
carbonyldiimidazole (48 mg, 0.30 mmol) in dry THF was heated at reflux overnight under an Ar
atmosphere. After completion, the reaction was cooled to room temperature, and the solvent was
evaporated under vacuum. The residue was acidified to pH 2 with 2 M HCl, and the precipitate was
filtered off. The filtrate was dried in vacuo, and a white solid was obtained. The crude residue was
purified by flash column chromatography (DCM/MeOH 95:5) to obtain product 5. Yield: 78%. TLC
(DCM/MeOH 9:1): Rf: 0.22. Mp: 305–308 ◦C. 1H-NMR (300 MHz, CD3OD): δ 7.06–7.04 (m, 4H, ArH)
ppm. 13C-NMR (75 MHz, CDCl3): δ 156.6, 129.4, 121.1, 108.9 ppm. Anal. calcd (%) for C7H6N2O: C,
62.68; H, 4.51; N, 20.88; found: C, 62.72; H, 4.58; N, 20.87.
3.3. Single Crystal X-ray Analysis
Diffraction data for compound 1 were collected by means of a Bruker AXS CCD-based
three-circle diffractometer (Bruker AXS, Karlsruhe, Germany), working at ambient temperature
with graphite-monochromatized Mo-Kα X-radiation (λ = 0.71073 Å).
X-ray diffraction data in the θ range of 2–30◦ were collected by acquiring 4 sets of 600 bidimensional
CCD frames with the following operative conditions: omega rotation axis, scan width 0.3◦, acquisition
time 30 s, sample-to-detector distance 50 mm, phi angle fixed at four different values (0◦, 90◦, 180◦, and
270◦) for the four different sets.
Omega-rotation frames were processed with the SAINT software (Bruker) for data reduction
(including intensity integration, background, Lorentz, and polarization corrections) and for
determination of accurate unit-cell dimensions, obtained by the least-squares refinement of the
positions of 6048 independent reflections with I > 10σ(I) in the θ range 2–25◦. Absorption effects were
empirically evaluated by the SADABS software [46], and absorption correction was applied to the data
(0.847 and 0.973 min and max transmission factors, respectively).
The structures were solved by direct methods (SIR-2014) [47] and completed by iterative cycles
of full-matrix least-squares refinement on Fo2 and ∆F synthesis using the SHELXL-17 [48] program
(WinGX suite) [49]. The positions of hydrogen atoms were introduced at calculated positions in their
described geometries and allowed to ride on the attached carbon atom with fixed isotropic thermal
parameters (1.2 Ueq of the parent carbon atom).
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These data can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html (or
from the Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB21EZ, UK;
Fax: +44-1223-336-033; or deposit@ccdc.cam.ac.uk). CCDC Number 1,982,708 number contains
the supplementary crystallographic data for this paper.
Crystal data for compound 1: C16H20N8O2S1, Mr = 396.48 g/mol, Tetragonal, Space group I41/a,
a = 14.1731 (7) Å, b = 14.1731 (7) Å, c = 18.0847 (9) Å, V = 3632.8 (5) Å3, Z = 8, Dcalc = 1.397 Mg/m3,
R = 0.049 (2655 reflections), wR2 = 0.133, T = 293 (2) K, GOF = 1.029. The reflections were collected in
the range 1.78◦ ≤ θ ≤ 29.98◦ employing a 0.41 × 0.13 × 0.013 mm crystal.
3.4. Biological Evaluation
AlphaScreen is a bead-based non-radioactive assay system for the detection of biomolecular
interactions in a microtiter plate format. The binding of biological partners brings donor and acceptor
beads into close proximity and, as a result, a fluorescent signal between 520 and 620 nm was produced.
The AlphaScreen-based assays [50,51] were performed in a final reaction volume of 25 µL of the
assay buffer containing 10 mM HEPES–NaOH (pH 7.4), 50 mM NaCl, 1 mM EDTA (pH 8.0), 0.1%
NP-40, and 10 ng/µL bovine serum albumin (BSA) in a 96-well microtiter plate at 25 ◦C. The pTyr
peptide probes used in this study were 5-carboxyfluorescein (FITC)-GpYLPQTV for STAT3 and
(FITC)-GpYDKPHVL for STAT1. Plasmid construction and protein expression were performed as
previously described [52]; the experimental method is briefly summarized as follows. Considering
that the expression of the full-length protein is troublesome, a truncated form of STAT3 (136-705)
was constructed and chromatographically purified (AKTA FPLC system; GE Healthcare Bio-Sciences,
Piscataway, NJ, USA). The soluble STAT3 fraction was loaded on a HisTrap™ column (GE Healthcare
Bio-Sciences) and eluted with an imidazole gradient (50 mM Tris–HCl pH 7.4, 300 mM NaCl, 0.2 mM
EDTA, 0.1% (w/v) NP-40, 5 mM β-mercaptoethanol, 10% (v/v) glycerol, and 10–300 mM imidazole).
An SDS-PAGE stained with Coomassie Brilliant Blue (CBB) was performed to check the purity of the
protein (see Figure S71). Subsequently, the protein was dialyzed (10 mM HEPES-NaOH pH 7.4, 50 mM
NaCl, 10 mM β-mercaptoethanol, 0.1 mM EGTA, 0.02% (w/v) NP-40, 0.2 mM phenylmethylsulphonyl
fluoride (PMSF), and 10% (v/v) glycerol).
Firstly, 75 nM of each SH2-containing protein were incubated with the test compound (at the
following concentrations: 1, 3, 10, and 30 µM) for 15 min. Each protein sample was then incubated
for 90 min with 50 nM of its corresponding FITC-pTyr peptide and simultaneously mixed with
streptavidin-coated donor beads and anti-FITC acceptor beads before detection at 570 nm using
EnVison Xcite (PerkinElmer, Waltham, MA, USA).
The same procedure was used to evaluate compound 1 activity versus STAT3 single-cysteine-
residue mutants (Cys468A, Cys542A, Cys550A, Cys687A, and Cys712A). Briefly, 3 µL of compound 1
in DMSO (at 0.3, 1, 3, 10 and 30 µM concentration) were premixed with 1 µL of L-Cys in PBS and 16 µL
of an AlphaScreen buffer. Then, the mixture was immediately (<5 min) mixed with the STAT3 mutant
solution before adding the FITC-peptide.
3.5. Analytical Studies
3.5.1. MS, UV, and LC Analyses
Sample Preparation
A compound 1 stock solution (1 mg/mL) was prepared in MeOH. The stock solution for GSH was
prepared at the same concentration in deionized water.
An aqueous buffer (10 mM) for experiments at pH 2 was prepared with 10 mM H3PO4/NaH2PO4,
whereas 10 mM NaH2PO4/Na2HPO4 and 10 mM NaHCO3/Na2CO3 were used for the physiological
buffer (pH 7.4) and the basic buffer (pH 10), respectively. For experiments under non-oxidizing
conditions, 5 mM Na2S2O5 was directly added into the buffers.
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Reaction batches were prepared by spiking into the desired buffer aliquots of stock solutions of
compound 1 and GSH down to 0.5 and 1 mM, respectively. All reactions were kept at 37 ◦C under
gentle stirring for up to 24 h.
Before MS experiments, all samples were diluted 1:10 with an aqueous solution containing 30%
acetonitrile and 0.1% formic acid to improve ionization.
Before LC injection, samples were diluted 1:5 with 24 mM HCl. No additional dilution/sample
treatment was required for UV spectroscopy.
MS Method
MS analyses were performed on an LTQ-Orbitrap™ XL mass spectrometer (Thermo Fisher
Scientific, Waltham, MA, USA) equipped with a Finnigan Ion Max 2 electro-spray source (ESI) endowed
with a metal capillary that was 140 mm long and had a 160 µm inner diameter.
Samples were taken with a Hamilton glass syringe. The solution was injected by a pre-installed
infuser at a flow rate of 5 µL/min. Nebulization was carried out in positive ion mode with a spray
voltage of 4 kV, 10 units of sheath gas at a capillary temperature of 275 ◦C, and an offset tube lens of
74 V. Orbitrap™ analyzer acquired mass spectra with a scan range from 200 to 1000 m/z, recording
5 × 105 ion per scan with a resolution of 100,000 (full-width at half-maximum at a 400 m/z).
UV Method
UV spectra were performed with a Shimadzu UV-1900 (Shimadzu, Kyoto, Japan) by using UV
PROBE 2.7 software (Shimadzu). Analyses were done with 1.5 mL quartz cuvettes (Hellma, Müllheim,
Germany), acquiring the spectra in a scan range from 200 to 600 nm.
LC Method
LC analysis was carried out with an HPLC Surveyor LC system (Thermo Finnigan) equipped
with a quaternary pump, diode array (PDA) detector, autosampler, online degasser, and thermostat.
Chromatographic separation was carried out with a Phenomenex® Kinetex C18 reverse-phase column
(Phenomenex, Torrance, CA, USA; 25 mm × 2.10 mm, 2.6 µm particle diameter with 100 Å pores).
An OPTI-SOLV® Mini Filter (0.5 mm; Sigma-Aldrich-Merck) was installed before the column to protect
it from particulates. A gradient program reported in Table 4 was used at 200 µL/min flow rate; as a
mobile phase, 1 mM HCl (pH 3) and acetonitrile were employed. The PDA detector worked in scan
mode, acquiring UV spectra in a range from 200 to 600 nm.
Table 4. LC-UV gradient program.
Time (min) 1 mM HCl, pH 3 (A) ACN (B)
0.00 95 5
1.00 95 5
16.00 30 70
16.50 30 70
16.51 95 5
22.00 95 5
3.5.2. 1H-NMR Analysis
1H-NMR analysis was performed at 500 MHz with a Bruker FT-NMR AVANCE™ DRX500
spectrometer (Bruker, Billerica, MA, USA) using a 5 mm z-PFG (pulsed field gradient) broadband
reverse probe at 298 K. The experimental procedure was designed as follows: a 10 mM pH 10 carbonate
buffer solution in D2O was used as the solvent for NMR analysis. Na2S2O5 (20 mg, 0.1 mmol) was
dissolved in 1 mL of the solvent, and (1) compound 1 (5 mg, 0.025 mmol), (2) GSH (16 mg, 0.05 mmol),
or (3) compound 1 (5 mg, 0.025 mmol) and GSH (16 mg, 0.05 mmol) were dissolved in 0.7 mL of such a
solution. Notably, when Na2S2O5 was added, the pH of the solution was slightly lowered below the
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value of 10 (pH ≤ 10). Each sample was immediately put into the NMR tube and analyzed (time 0)
at 298 K. Then, they were heated at 37 ◦C in a thermostatic bath, and their 1H-NMR spectra were
collected after different times at 298 K.
4. Conclusions
Benzothiadiazole derivative 1 was identified as a novel STAT3 inhibitor by structure-based virtual
screening performed on the SH2 domain. The AlphaScreen-based assay confirmed, albeit indirectly,
that compound 1 was able to inhibit STAT3 dimerization, exhibiting a good activity (STAT3 IC50 =
15.8 ± 0.6 µM versus STAT1 IC50 > 50 µM). Therefore, a small set of derivatives was designed and
synthesized through a flexible diversity-oriented synthetic approach when required. The compounds
were tested to define the main structural features for the lead development. Among them, only
compound 1d exhibited a significant, albeit reduced, activity, thus suggesting a considerably “tight”
SAR for this class of derivatives. Moreover, because compound 1, like other known STAT3 inhibitors,
probably binds to cysteine residues, MS, UV, LC, and NMR studies were performed to understand
its mechanism of interaction. Mimicking the biological conditions, we conducted an MS analysis of
compound 1 in the presence of GSH: We discovered that this inhibitor can covalently bind to cysteine
residues through a Michael-like reaction, leading to the formation of some alkylation adducts.
In an attempt to confirm the results of the MS study, an NMR investigation was carried out
to further characterize the adducts formed by the interaction of compound 1 with GSH. However,
despite the same reaction conditions (pH, temperature, and use of an antioxidant) being employed,
the intrinsic differences between the two techniques prevented us from obtaining additional evidence
to support the MS conclusions. Notably, NMR spectroscopy is seldom used for this kind of study
in the literature [16,18], which suggests that its inherent limitations make it unsuitable for such an
application. Therefore, it would seem reasonable to claim that the NMR results neither supported nor
disproved our hypotheses.
The research of STAT3 inhibitors has led to several potent anti-tumor candidates over the years
(e.g., Stattic, S3I-201, and erasin). In this context, we are confident that our ongoing studies will
allow us to develop and improve our lead compound 1 as a new PPI inhibitor endowed with a novel
mechanism of interaction and characterized by a pH-dependent activation.
Supplementary Materials: The following are available online: Tables S1–S5: Top-ranked compounds from
computational studies; Figure S1: Main SH2 domain residues involved in the interaction with compound 1;
Table S6: Pan-assay interference compound (PAINS) in silico prediction test, employing five on-line services
(SmartsFilter, SwissADME, Zinc Patterns, FAF-Drugs4, and PAINS remover); Figures S2–S70: 1H and 13C-NMR
spectra of synthesized compounds; Table S7: Effect of cysteine on the inhibitory activity of compound 1 versus
STAT3; Table S8: Effect of the mutation of cysteine residues located in the vicinities of the SH2 domain on
the inhibitory activity of compound 1 versus STAT3; Figure S71: CBB staining of the STAT3(136–705) and
STAT5b(136–703) proteins. The purified soluble proteins (0.5 µg) were analyzed by SDS-PAGE; Table S9:
Comparison of the best STAT3 complexes obtained by docking compound 1 into the pockets containing the
mutated cysteines, considered in the mutagenesis study; Figure S72: Main interactions of compound 1 into the
pocket lined by Cys712; Page S52: NMR studies; Figure S73–S75: 1H-NMR full spectra and expansions related to
the NMR analysis of compound 1/GSH.
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